| Company
| InsiderPie Expert Score
| P/E ratio
| Gross margin
| EBIT margin
| ROA
| Net income per employee
|
| Vaccinex, Inc.
|
50
/ 100
| -0.1
| -547.4%
| -3,117.3%
| -717.8%
| -€695.13K
|
| AIM ImmunoTech Inc.
|
50
/ 100
| -0.4
| 71.1%
| 2,614.0%
| -391.5%
| -€660.50K
|
| Hefei Lifeon Pharmaceutical Co., Ltd.
|
50
/ 100
| 28
| 66.0%
| 12.6%
| 6.3%
| €13.55K
|
| Mersana Therapeutics, Inc.
|
50
/ 100
| -0.64
| 99.2%
| -207.0%
| -87.5%
| -€622.78K
|
| Madrigal Pharmaceuticals, Inc.
|
52
/ 100
| -23
| 95.3%
| -41.5%
| -21.2%
| -€469.83K
|
| Hyloris Pharmaceuticals SA
|
50
/ 100
| -26
| 97.7%
| -71.0%
| -15.3%
| -€129.43K
|
| Prelude Therapeutics Incorporated
|
50
/ 100
| -0.49
| 93.8%
| -1,928.7%
| -108.2%
| -€814.24K
|
| Iovance Biotherapeutics, Inc.
|
50
/ 100
| -1.9
| 20.6%
| -170.0%
| -43.0%
| -€399.23K
|
| BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.
|
50
/ 100
| 47
| 56.9%
| 21.7%
| 4.4%
| €7.66K
|
| ProKidney Corp.
|
50
/ 100
| -3.8
| 100.0%
| -34,467.0%
| -19.5%
| -€304.82K
|
| ACADIA Pharmaceuticals Inc.
|
54
/ 100
| 17
| 92.0%
| 23.2%
| 18.1%
| €291.90K
|
| Poseida Therapeutics, Inc.
|
50
/ 100
| -16
| 95.4%
| -41.4%
| -20.2%
| -€145.62K
|
| GI Innovation, Inc.
|
50
/ 100
| -17K
| -633.5%
| -22,340.0%
| -39.6%
| -€398.50K
|
| Bellicum Pharmaceuticals, Inc.
|
50
/ 100
| -0.036
| 100.0%
| -1,528.7%
| -318.1%
| -€1.44M
|
| Codiak BioSciences, Inc.
|
50
/ 100
| 0
| 100.0%
| -158.8%
| -21.8%
| -€245.92K
|
| ExpreS2ion Biotech Holding AB (publ)
|
50
/ 100
| -1.2
| -31.8%
| -1,455.8%
| -64.7%
| -€217.20K
|
| MannKind Corporation
|
52
/ 100
| 40
| 75.2%
| 23.2%
| 5.9%
| €62.24K
|
| BioGend Therapeutics Co., Ltd.
|
50
/ 100
| -31
| 74.9%
| -67.2%
| -15.0%
| -€102.80K
|
| Veru Inc.
|
50
/ 100
| -3
| 39.9%
| -512.6%
| -119.7%
| -€133.65K
|
| Lukas Biomedical Inc.
|
50
/ 100
| -6.9
| 57.5%
| -41.7%
| -37.5%
| -€52.98K
|
| RenovoRx, Inc.
|
50
/ 100
| -4.7
| 62.8%
| -1,699.1%
| -78.2%
| -€914.97K
|
| Innovation Pharmaceuticals Inc.
|
50
/ 100
| -0.04
| 4,683.3%
| 42,733.3%
| -39.8%
| -€568.64K
|
| Orthocell Limited
|
50
/ 100
| -19
| 65.8%
| -195.1%
| -44.7%
| €0.00
|
| ValiRx plc
|
50
/ 100
| -0.0046
| -780.2%
| -7,528.8%
| -92.8%
| -€282.51K
|
| FunPep Company Limited
|
50
/ 100
| -3.3
| -617.9%
| -21,425.0%
| -47.0%
| -€485.05K
|
| Pure Biologics Spólka Akcyjna
|
50
/ 100
| -1.1
| 9,866.7%
| 284,933.3%
| -678.8%
| -€933.87K
|
| BridgeBio Pharma, Inc.
|
58
/ 100
| -9.6
| 96.2%
| -172.2%
| -79.9%
| -€943.35K
|
| Arovella Therapeutics Limited
|
50
/ 100
| -9.9
| 85.6%
| -9,423.8%
| -45.9%
| €0.00
|
| Qingdao Vland Biotech Inc.
|
50
/ 100
| 59
| 45.2%
| 9.1%
| 2.0%
| €4.64K
|
| CrystalGenomics, Inc.
|
50
/ 100
| -3.4
| 5.0%
| -281.0%
| -18.3%
| -€403.79K
|
| MYND Life Sciences Inc.
|
50
/ 100
| -6.2
| -143.7%
| -2,979.4%
| -75.4%
| €0.00
|
| Samsung Biologics Co.,Ltd.
|
50
/ 100
| 57
| 38.4%
| 32.3%
| 7.2%
| €157.76K
|
| Malachite Innovations, Inc.
|
50
/ 100
| 0
| 25.2%
| -2.8%
| -4.4%
| -€4.99K
|
| Cuorips Inc.
|
50
/ 100
| -84
| 52.3%
| -336.9%
| -11.2%
| -€60.24K
|
| Inovio Pharmaceuticals, Inc.
|
50
/ 100
| -0.67
| 100.0%
| -17,300.3%
| -79.0%
| -€630.06K
|
| PhoenixBio Co., Ltd.
|
50
/ 100
| -5.8
| 72.5%
| -18.7%
| -19.5%
| -€35.06K
|
| LENZ Therapeutics, Inc.
|
50
/ 100
| -13
| 99.8%
| -1,239.2%
| -24.1%
| -€7.49M
|
| Taiwan Advance Bio-Pharmaceutical Inc.
|
50
/ 100
| 28
| 66.8%
| 10.3%
| 6.5%
| €8.00K
|
| Porton Pharma Solutions Ltd.
|
50
/ 100
| -6.6K
| 28.6%
| 0.5%
| -0.0%
| -€34.78
|
| Imugene Limited
|
50
/ 100
| -0.51
| 100.0%
| -1,746.8%
| -261.6%
| €0.00
|
| Sunny Pharmtech Inc.
|
50
/ 100
| -7.1
| 50.1%
| -29.1%
| -21.4%
| -€57.14K
|
| Oncternal Therapeutics, Inc.
|
50
/ 100
| -0.045
| -1,017.6%
| -2,157.1%
| -221.6%
| -€1.10M
|
| 4D Molecular Therapeutics, Inc.
|
50
/ 100
| -1
| 4,130.3%
| -667,654.5%
| -41.4%
| -€741.37K
|
| Medigene AG
|
50
/ 100
| -0.12
| 78.4%
| -242.9%
| -57.8%
| -€191.39K
|
| Molecular Templates, Inc.
|
50
/ 100
| -0.000042
| 63.3%
| -33.7%
| -58.5%
| -€216.24K
|
| RemeGen Co Ltd
|
50
/ 100
| -38
| 78.5%
| -69.8%
| -25.9%
| -€55.60K
|
| Ceapro Inc.
|
50
/ 100
| -0.11
| 37.1%
| -92.8%
| -21.1%
| €0.00
|
| Sino Biopharmaceutical Limited
|
50
/ 100
| 170
| 81.8%
| 21.1%
| 5.2%
| €19.28K
|
| Neovacs S.A.
|
50
/ 100
| -0.000099
| -1,562.7%
| -1,657.8%
| -188.7%
| -€1.89M
|
| Futura Medical plc
|
50
/ 100
| -0.054
| 66.2%
| -34.3%
| -38.4%
| -€426.07K
|
| Kidswell Bio Corporation
|
50
/ 100
| -564
| 32.3%
| 0.5%
| -0.3%
| -€3.07K
|
| Compugen Ltd.
|
50
/ 100
| -29
| 62.3%
| -89.5%
| -18.2%
| -€224.52K
|
| Aadi Bioscience, Inc.
|
50
/ 100
| -9
| 89.1%
| -473.8%
| -5.8%
| -€223.47K
|
| ArcticZymes Technologies ASA
|
50
/ 100
| 454
| 96.8%
| -7.7%
| 0.5%
| €2.99K
|
| Autolus Therapeutics plc
|
50
/ 100
| -2.6
| -87.4%
| -902.6%
| -31.6%
| -€302.06K
|
| ACRO Biomedical Co., Ltd.
|
50
/ 100
| 0.0054
| 17.8%
| -3,072.9%
| 20,753.6%
| €0.00
|
| Pyxis Oncology, Inc.
|
50
/ 100
| -0.82
| 72.7%
| -1,706.8%
| -91.9%
| -€1.89M
|
| Neurobiological Technologies, Inc.
|
50
/ 100
| 0.00024
| 100.0%
| 41.2%
| 37.9%
| €2.42M
|
| Eledon Pharmaceuticals, Inc.
|
50
/ 100
| 12
| 100.0%
| -45,682.8%
| 10.1%
| €405.28K
|
| Serina Therapeutics Inc
|
50
/ 100
| -6.3
| 50.0%
| -15,475.0%
| -140.8%
| -€900.26K
|
| Vectus Biosystems Limited
|
50
/ 100
| -0.62
| 98.2%
| -286.7%
| -525.8%
| €0.00
|
| Mera Pharmaceuticals, Inc.
|
50
/ 100
| -0.29
| 94.6%
| -66.4%
| -265.5%
| €0.00
|
| Palvella Therapeutics, Inc.
|
50
/ 100
| -33
| 0.0%
| -1,801.9%
| -33.6%
| -€1.52M
|
| Proteomics International Laboratories Limited
|
50
/ 100
| -4.8
| -7.5%
| -228.5%
| -185.3%
| €0.00
|
| Nova Mentis Life Science Corp.
|
50
/ 100
| 9.8
| 106.7%
| 1,586.5%
| 5.7%
| €0.00
|
| Arrowhead Pharmaceuticals, Inc.
|
49
/ 100
| -16
| 35.4%
| -13.2%
| -10.9%
| -€212.74K
|
| Kymera Therapeutics, Inc.
|
50
/ 100
| -11
| 88.9%
| -759.7%
| -26.8%
| -€1.22M
|
| Protalix BioTherapeutics, Inc.
|
50
/ 100
| 20
| 57.5%
| 13.3%
| 8.0%
| €25.28K
|
| Arvinas, Inc.
|
50
/ 100
| -9.6
| 99.0%
| -32.7%
| -6.9%
| -€116.73K
|
| Caribou Biosciences, Inc.
|
50
/ 100
| -0.67
| 87.0%
| -1,837.6%
| -74.4%
| -€958.76K
|
| Shandong Sito Bio-technology Co., Ltd.
|
50
/ 100
| -20
| 7.8%
| -20.7%
| -6.0%
| -€21.86K
|
| ISR Immune System Regulation Holding AB (publ)
|
50
/ 100
| -4.7
| -31,352.9%
| -39,744.5%
| -121.0%
| -€378.11K
|
| Atara Biotherapeutics, Inc.
|
50
/ 100
| 2.6
| 81.6%
| 17.3%
| 77.6%
| €131.23K
|
| Caladrius Biosciences, Inc.
|
50
/ 100
| -0.2
| 100.9%
| -16.2%
| -66.2%
| -€529.16K
|
| Intellipharmaceutics International Inc.
|
50
/ 100
| -1
| 3.5%
| -285.1%
| -224.7%
| -€274.49K
|
| Immix Biopharma, Inc.
|
50
/ 100
| -2.9
| -121.3%
| -24,699.0%
| -147.9%
| -€1.10M
|
| Kazia Therapeutics Limited
|
50
/ 100
| -0.29
| 100.0%
| -1,570.5%
| -155.9%
| -€2.13M
|
| hVIVO plc
|
50
/ 100
| 0.03
| 60.9%
| 18.2%
| 30.1%
| €140.39K
|
| Benitec Biopharma Inc.
|
50
/ 100
| -11
| 50.0%
| -7,511.7%
| -38.1%
| -€2.03M
|
| MorphoSys AG
|
50
/ 100
| -5.4
| 79.8%
| -219.7%
| -25.1%
| -€991.95K
|
| Cline Scientific AB (publ)
|
50
/ 100
| -0.99
| 97.7%
| -74.0%
| -13.9%
| -€143.75K
|
| Hangzhou Biotest Biotech Co.,Ltd.
|
50
/ 100
| 43
| 52.6%
| 25.2%
| 4.5%
| €22.09K
|
| Q BioMed Inc.
|
50
/ 100
| 0.0098
| -450.1%
| 14,212.5%
| 0.0%
| €422.15K
|
| Genovis AB (publ.)
|
50
/ 100
| 64
| 89.1%
| 30.5%
| 8.1%
| €76.94K
|
| D. Western Therapeutics Institute, Inc.
|
50
/ 100
| -4.3
| 84.5%
| -222.8%
| -70.0%
| -€294.09K
|
| Axsome Therapeutics, Inc.
|
44
/ 100
| -23
| 91.9%
| -37.8%
| -34.3%
| -€276.59K
|
| Formycon AG
|
50
/ 100
| -4.7
| 6.3%
| -54.4%
| -14.3%
| -€423.49K
|
| Cyclerion Therapeutics, Inc.
|
50
/ 100
| -5.2
| 95.7%
| -172.7%
| -20.8%
| -€1.67M
|
| Biohit Oyj
|
50
/ 100
| 11
| 55.5%
| 14.5%
| 22.0%
| €84.78K
|
| Geffen Residence & Renewal Ltd
|
50
/ 100
| -87
| 100.0%
| -6,579.8%
| -4.9%
| -€29.94K
|
| INmune Bio, Inc.
|
50
/ 100
| -3.8
| 100.0%
| -102,752.0%
| -149.6%
| -€3.29M
|
| Cibus, Inc.
|
50
/ 100
| -0.19
| 100.0%
| -5,736.2%
| -79.5%
| -€1.50M
|
| Vicore Pharma Holding AB (publ)
|
50
/ 100
| -5.9
| 92.8%
| -4,610.9%
| -38.0%
| -€1.03M
|
| MiNK Therapeutics, Inc.
|
50
/ 100
| -0.011
| -0.0%
| -0.3%
| -111,704.5%
| -€103.53M
|
| MacroGenics, Inc.
|
50
/ 100
| -3
| 86.8%
| -47.6%
| -14.8%
| -€91.58K
|
| Zelira Therapeutics Limited
|
50
/ 100
| -0.12
| -2,291.7%
| -11,004.5%
| -3,090.4%
| -€2.86M
|
| Incyte Corporation
|
65
/ 100
| 11
| 92.9%
| 30.8%
| 18.8%
| €389.68K
|
| Taiwan Bio Therapeutics Co., Ltd
|
50
/ 100
| -6
| 56.9%
| -264.7%
| -31.5%
| €0.00
|
| Nuvation Bio Inc.
|
50
/ 100
| -3.4
| 54.3%
| -871.0%
| -36.2%
| -€848.17K
|
| Jilin Jian Yisheng Pharmaceutical Co., Ltd.
|
50
/ 100
| 66
| 74.5%
| 7.9%
| 1.4%
| €2.96K
|
| Coeptis Therapeutics, Inc.
|
50
/ 100
| -2.9
| 31.7%
| -605.6%
| -85.1%
| -€1.78M
|
| Shine-On BioMedical Co.,Ltd.
|
50
/ 100
| -20
| 24.6%
| -2,349.7%
| -19.1%
| -€234.87K
|
| ORIC Pharmaceuticals, Inc.
|
50
/ 100
| -4.9
| 41.8%
| -27,771.7%
| -31.4%
| -€951.33K
|
| Oncimmune Holdings plc
|
50
/ 100
| 0.027
| 41.2%
| -199.3%
| 9.7%
| €13.61K
|
| Mycenax Biotech Inc.
|
50
/ 100
| -15
| -31.0%
| -61.5%
| -15.4%
| €0.00
|
| Celularity Inc.
|
50
/ 100
| -0.54
| 70.3%
| -119.6%
| -70.6%
| -€576.61K
|
| Gwo Xi Stem Cell Applied Technology Co. , Ltd
|
50
/ 100
| -16
| 61.2%
| -47.5%
| -17.2%
| -€97.54K
|
| PharmaResearch Co., Ltd.
|
50
/ 100
| 43
| 74.0%
| 37.6%
| 13.8%
| €182.15K
|
| Silo Pharma, Inc.
|
50
/ 100
| -0.87
| 91.9%
| -7,165.0%
| -73.6%
| -€1.40M
|
| BioLASCO Taiwan Co., Ltd.
|
50
/ 100
| 17
| 41.7%
| 19.9%
| 8.0%
| €14.72K
|
| Cynata Therapeutics Limited
|
50
/ 100
| -2.1
| 93.3%
| -779.5%
| -265.8%
| €0.00
|
| SK bioscience Co.,Ltd.
|
50
/ 100
| -70
| 8.5%
| -26.7%
| -1.8%
| -€31.34K
|
| TOT BIOPHARM International Company Limited
|
50
/ 100
| 84
| 71.5%
| 1.6%
| 1.1%
| €3.22K
|
| Regen BioPharma, Inc.
|
50
/ 100
| -1.1
| 100.0%
| -127.6%
| -441.3%
| -€745.30K
|
| Keros Therapeutics, Inc.
|
50
/ 100
| 30
| 99.7%
| 0.1%
| 2.5%
| €98.82K
|
| Regeneron Pharmaceuticals, Inc.
|
61
/ 100
| 12
| 84.4%
| 26.0%
| 11.4%
| €259.13K
|
| Applied Genetic Technologies Corporation
|
50
/ 100
| 0
| 100.0%
| -15,888.3%
| -61.5%
| -€296.53K
|
| Tarsus Pharmaceuticals, Inc.
|
50
/ 100
| -21
| 88.8%
| -23.9%
| -15.2%
| -€215.58K
|
| Innoviva, Inc.
|
50
/ 100
| 11
| 84.8%
| -3.2%
| 8.9%
| €860.32K
|
| Advicenne S.A.
|
50
/ 100
| -1.5
| 14.0%
| -134.0%
| -218.7%
| -€700.86K
|
| Kexing Biopharm Co., Ltd.
|
50
/ 100
| 111
| 64.5%
| 7.5%
| 3.0%
| €8.62K
|
| Arterra Bioscience
|
50
/ 100
| 6.3
| 26.9%
| 16.9%
| 18.0%
| €80.43K
|
| Bioneer Corporation
|
50
/ 100
| -24
| 76.2%
| -2.0%
| -4.6%
| -€16.46K
|
| Biodexa Pharmaceuticals Plc
|
50
/ 100
| -0.0000011
| -8,531.3%
| -20,463.9%
| -88.0%
| -€1.15M
|
| Mendus AB (publ)
|
50
/ 100
| -2.5
| 5.1%
| -3,130.2%
| -16.7%
| -€351.33K
|
| MegaPro Biomedical Co., Ltd
|
50
/ 100
| -4.2
| -106,206.3%
| -998,918.8%
| -182.3%
| -€301.51K
|
| Vericel Corporation
|
50
/ 100
| 313
| 73.5%
| 0.5%
| 1.6%
| €17.08K
|
| OptiBiotix Health Plc
|
50
/ 100
| -0.042
| 34.1%
| -269.7%
| -34.7%
| -€363.02K
|
| Eyenovia, Inc.
|
50
/ 100
| -0.24
| -7,177.3%
| -85,888.3%
| -71.9%
| -€2.64M
|
| OBI Pharma, Inc.
|
50
/ 100
| -3.8
| -122.4%
| -3,964.4%
| -55.8%
| -€255.12K
|
| BRIM Biotechnology, Inc.
|
50
/ 100
| -5.2
| 1.7%
| -43,729.4%
| -38.8%
| €0.00
|
| Guanhao Biotech Co.,Ltd.
|
50
/ 100
| 171
| 78.7%
| 7.2%
| 3.4%
| €5.97K
|
| Sutro Biopharma, Inc.
|
49
/ 100
| -0.33
| 96.4%
| -196.3%
| -79.5%
| -€665.66K
|
| Argenica Therapeutics Limited
|
50
/ 100
| -9.7
| 100.0%
| -293.4%
| -83.4%
| €0.00
|
| Seelos Therapeutics, Inc.
|
50
/ 100
| 0.053
| 60.3%
| -1,480.0%
| 171.8%
| €438.76K
|
| Gelesis Holdings, Inc.
|
50
/ 100
| -0.00014
| -61.4%
| -546.5%
| -53.9%
| -€476.66K
|
| Aptamer Group plc
|
50
/ 100
| -0.0071
| -2.8%
| -312.8%
| -213.4%
| -€378.70K
|
| Transgene Biotek Limited
|
50
/ 100
| -23
| 100.0%
| -150.1%
| 0.0%
| €0.00
|
| Altimmune, Inc.
|
50
/ 100
| -6.1
| -50.0%
| -471,850.0%
| -46.1%
| -€1.28M
|
| Jounce Therapeutics, Inc.
|
50
/ 100
| -1.9
| 100.0%
| -63.7%
| -24.0%
| -€309.85K
|
| Minerva Neurosciences, Inc.
|
50
/ 100
| 1.8
| 15.1%
| -43,917.6%
| 22.2%
| €723.88K
|
| Capricor Therapeutics, Inc.
|
50
/ 100
| -7.3
| -86.3%
| -778.8%
| -64.8%
| -€439.67K
|
| Biotron Limited
|
50
/ 100
| -0.71
| 98.8%
| -157.3%
| -383.0%
| -€534.94K
|
| Cytocom, Inc.
|
50
/ 100
| -86
| 100.0%
| -6,347.9%
| -19.1%
| -€125.73K
|
| 2seventy bio, Inc.
|
50
/ 100
| -65
| 52.0%
| -124.2%
| -0.9%
| -€54.01K
|
| 4D pharma plc
|
50
/ 100
| 0
| 100.0%
| -27,014.7%
| -56.1%
| -€257.56K
|
| BrightPath Biotherapeutics Co., Ltd.
|
50
/ 100
| -3.2
| -433.1%
| -1,013,441.5%
| -85.0%
| -€159.44K
|
| Kancera AB (publ)
|
50
/ 100
| -3.2
| 100.0%
| -291,892.9%
| -85.4%
| -€728.44K
|
| Arcellx, Inc.
|
50
/ 100
| -19
| 97.2%
| -376.3%
| -30.4%
| -€989.54K
|
| Soleno Therapeutics, Inc.
|
50
/ 100
| -22
| 97.9%
| -446.6%
| -54.5%
| -€1.35M
|
| Baolingbao Biology Co.,Ltd.
|
50
/ 100
| 30
| 13.1%
| 7.0%
| 5.3%
| €12.54K
|
| Berkeley Lights, Inc.
|
50
/ 100
| -0.87
| 69.4%
| -123.3%
| -33.3%
| -€301.15K
|
| Jaguar Health, Inc.
|
50
/ 100
| -0.12
| 81.8%
| -279.1%
| -84.2%
| -€711.70K
|
| Shanghai Model Organisms Center, Inc.
|
50
/ 100
| 65
| 49.6%
| 7.0%
| 1.8%
| €5.29K
|
| Entrada Therapeutics, Inc.
|
50
/ 100
| -4.1
| 96.2%
| -121.0%
| -16.3%
| -€343.92K
|
| Arena Pharmaceuticals, Inc.
|
50
/ 100
| 0
| 100.0%
| -1,158,285.2%
| -78.7%
| -€1.18M
|
| G1 Therapeutics, Inc.
|
50
/ 100
| -8.4
| 89.4%
| -65.1%
| -45.4%
| -€384.13K
|
| Editas Medicine, Inc.
|
50
/ 100
| -0.72
| 92.3%
| -616.9%
| -112.5%
| -€826.12K
|
| Bio-Techne Corporation
|
53
/ 100
| 104
| 65.5%
| 9.3%
| 3.1%
| €21.58K
|
| Shenzhen Bioeasy Biotechnology Co., Ltd.
|
50
/ 100
| 188
| 68.6%
| 9.8%
| 1.5%
| €5.31K
|
| Endonovo Therapeutics, Inc.
|
50
/ 100
| -0.011
| -4,515.3%
| -15,532.6%
| -14,502.0%
| -€2.40M
|
| Paratek Pharmaceuticals, Inc.
|
50
/ 100
| -1.9
| 84.9%
| -26.6%
| -46.0%
| -€214.89K
|
| EZZ Life Science Holdings Limited
|
50
/ 100
| 6
| 74.3%
| 17.7%
| 40.3%
| €0.00
|
| Scancell Holdings plc
|
50
/ 100
| -0.056
| 55.8%
| -706.2%
| -78.5%
| -€339.85K
|
| Savior Lifetec Corporation
|
50
/ 100
| 14
| 35.7%
| 16.5%
| 11.2%
| €32.84K
|
| U.S. Stem Cell, Inc.
|
50
/ 100
| -0.11
| 75.4%
| -1,873.6%
| 0.0%
| €0.00
|
| OmniAb, Inc.
|
50
/ 100
| -3.1
| 30.7%
| -309.7%
| -21.5%
| -€478.04K
|
| Assembly Biosciences, Inc.
|
50
/ 100
| -3.4
| 99.9%
| -184.3%
| -48.2%
| -€457.96K
|
| AnnJi
|
50
/ 100
| -8.7
| -12.3%
| 206.0%
| -65.5%
| €0.00
|
| CorMedix Inc.
|
47
/ 100
| 6.1
| 92.6%
| 48.5%
| 21.6%
| €2.18M
|
| Plant Advanced Technologies SA
|
50
/ 100
| -15
| -62.2%
| -65.7%
| -5.2%
| -€13.75K
|
| Shanghai Junshi Biosciences Co., Ltd.
|
50
/ 100
| -34
| 78.1%
| -50.4%
| -9.0%
| -€49.38K
|
| Viridian Therapeutics, Inc.
|
50
/ 100
| -4.4
| 99.8%
| -463.5%
| -52.3%
| -€1.81M
|
| Timber Pharmaceuticals, Inc.
|
50
/ 100
| -0.078
| -10,393.9%
| -17,664.2%
| -452.4%
| -€1.43M
|
| Xilio Therapeutics, Inc.
|
50
/ 100
| -0.64
| 100.0%
| -377.4%
| -42.0%
| -€753.73K
|
| U-Neuron Biomedical Inc
|
50
/ 100
| -16
| 68.2%
| -128.2%
| -14.3%
| €0.00
|
| ADR120S, Inc.
|
50
/ 100
| -3.5
| -13.3%
| -665.0%
| -60.5%
| -€1.18M
|
| Ascentage Pharma Group International
|
50
/ 100
| -22
| 94.6%
| -128.0%
| -35.4%
| -€227.92K
|
| Nxera Pharma Co., Ltd.
|
50
/ 100
| -26
| 72.5%
| -17.5%
| -2.3%
| -€46.64K
|
| Enochian Biosciences, Inc.
|
50
/ 100
| -0.89
| 50.0%
| -43,620.8%
| -56.9%
| -€2.61M
|
| NanoCarrier Co., Ltd.
|
50
/ 100
| -10
| 72.7%
| -650.8%
| -22.4%
| -€269.66K
|
| Azitra, Inc.
|
50
/ 100
| -0.00082
| 101.6%
| -187,956.3%
| -77.7%
| -€219.84M
|
| Oncocross Co., Ltd.
|
50
/ 100
| -14
| 70.3%
| -720.4%
| -37.2%
| -€137.13K
|
| 4basebio PLC
|
50
/ 100
| -0.068
| 21.7%
| -1,228.4%
| -65.8%
| -€274.49K
|
| MedMira Inc.
|
50
/ 100
| -13
| 70.3%
| -1,472.5%
| -123.4%
| €0.00
|
| Legend Biotech Corporation
|
51
/ 100
| -11
| 61.8%
| -27.2%
| -19.3%
| -€107.51K
|
| Halozyme Therapeutics, Inc.
|
50
/ 100
| 11
| 84.5%
| 59.3%
| 26.8%
| €1.46M
|
| Bioxytran, Inc.
|
50
/ 100
| -5
| 96.5%
| 5,242.6%
| -1,507.0%
| -€635.73K
|
| Upstream Bio, Inc.
|
50
/ 100
| -11
| 100.0%
| -4,464.6%
| -24.8%
| -€1.72M
|
| Greenwich LifeSciences, Inc.
|
50
/ 100
| -7.2
| 25.7%
| -502,256.3%
| -575.7%
| -€3.86M
|
| Anhui Huaheng Biotechnology Co., Ltd.
|
50
/ 100
| 53
| 21.9%
| 5.9%
| 2.9%
| €8.57K
|
| ALK-Abelló A/S
|
50
/ 100
| 42
| 65.0%
| 23.1%
| 12.1%
| €48.89K
|
| Equillium, Inc.
|
50
/ 100
| -0.68
| 99.6%
| -123.7%
| -162.9%
| -€495.04K
|
| CytomX Therapeutics, Inc.
|
49
/ 100
| 9.3
| 100.0%
| 30.6%
| 27.4%
| €345.96K
|
| Eton Pharmaceuticals, Inc.
|
50
/ 100
| -61
| 51.4%
| -3.8%
| -6.4%
| -€184.94K
|
| Sonnet BioTherapeutics Holdings, Inc.
|
50
/ 100
| -0.27
| -345.6%
| -1,405.9%
| -659.6%
| -€894.71K
|
| HAVN Life Sciences Inc.
|
50
/ 100
| -1.8
| 690.9%
| 6,222.1%
| 0.0%
| €0.00
|
| Protagonist Therapeutics, Inc.
|
50
/ 100
| 66
| 99.7%
| 11.8%
| 7.2%
| €360.07K
|
| Albireo Pharma, Inc.
|
50
/ 100
| -6.7
| 95.6%
| -214.2%
| -42.8%
| -€906.71K
|
| Nascent Biotech, Inc.
|
50
/ 100
| -0.018
| -8,756,744.3%
| -61,998,933.6%
| -846.5%
| €0.00
|
| Verve Therapeutics, Inc.
|
50
/ 100
| -3.1
| 100.0%
| -349.7%
| -29.5%
| -€566.80K
|
| Britannia Life Sciences Inc.
|
50
/ 100
| 1.3
| 92.7%
| 206.9%
| 75.8%
| €0.00
|
| Xeris Biopharma Holdings, Inc.
|
50
/ 100
| -45
| 83.5%
| 3.7%
| -4.2%
| -€34.06K
|
| SK Biopharmaceuticals Co., Ltd.
|
50
/ 100
| 29
| 93.1%
| 23.8%
| 26.9%
| €621.59K
|
| Histogen Inc.
|
50
/ 100
| -0.0069
| -826.3%
| -63,447.4%
| -213.2%
| -€1.52M
|
| Gemina Laboratories Ltd.
|
50
/ 100
| -16
| -416.7%
| -35,059.9%
| -338.0%
| -€415.18K
|
| Amplia Therapeutics Limited
|
50
/ 100
| -2.1
| 92.9%
| -163.5%
| -48.3%
| -€6.31M
|
| Noile-Immune Biotech Inc.
|
50
/ 100
| -8.2
| 100.0%
| -13,610.9%
| -18.9%
| -€190.72K
|
| Amicogen, Inc.
|
50
/ 100
| -4.4
| 25.8%
| -9.1%
| -19.4%
| -€129.09K
|
| Abnova (Taiwan) Corporation
|
50
/ 100
| -271
| 44.3%
| 7.1%
| -0.5%
| -€1.64K
|
| Kadmon Holdings, Inc.
|
50
/ 100
| 0
| 93.8%
| -727.7%
| -39.5%
| -€812.09K
|
| Universal Ibogaine Inc.
|
50
/ 100
| -0.79
| 100.0%
| -47.4%
| -147.6%
| €0.00
|
| Spero Therapeutics, Inc.
|
50
/ 100
| -2.9
| 100.0%
| -142.0%
| -87.7%
| -€1.46M
|
| THC Farmaceuticals, Inc.
|
50
/ 100
| 2.9
| 81.0%
| -192.8%
| 1.7%
| €0.00
|
| Dyadic International, Inc.
|
50
/ 100
| -5.4
| 75.2%
| -132.1%
| -68.5%
| -€797.32K
|
| Asymchem Laboratories (Tianjin) Co., Ltd.
|
50
/ 100
| 30
| 41.6%
| 18.6%
| 5.2%
| €13.14K
|
| Relief Therapeutics Holding AG
|
50
/ 100
| -0.35
| 10.4%
| -249.6%
| -131.9%
| -€2.17M
|
| Emmaus Life Sciences, Inc.
|
50
/ 100
| -0.15
| 92.2%
| -10.2%
| -35.1%
| -€183.94K
|
| ABIVAX SA
|
50
/ 100
| -1.1
| 91.8%
| -3,281.1%
| -311.6%
| -€5.40M
|
| Bio-Gene Technology Limited
|
50
/ 100
| -1.2
| -4,130.5%
| -33,586.9%
| -206.2%
| €0.00
|
| Oragenics, Inc.
|
50
/ 100
| -0.34
| 0.0%
| -303.6%
| -481.4%
| -€2.95M
|
| Champions Oncology, Inc.
|
50
/ 100
| 30
| 5.2%
| 8.8%
| 9.6%
| €11.94K
|
| Tissue Repair Ltd
|
50
/ 100
| -1.2
| 79.2%
| -217.2%
| -57.5%
| €0.00
|
| Aileron Therapeutics, Inc.
|
50
/ 100
| -0.73
| 50.0%
| -48,688.9%
| -102.9%
| -€3.38M
|
| Berry Genomics Co.,Ltd
|
50
/ 100
| -19
| 44.2%
| -25.1%
| -10.9%
| -€21.41K
|
| Vaxart, Inc.
|
50
/ 100
| -2
| 100.0%
| -68.8%
| -34.5%
| -€462.85K
|
| Ocular Therapeutix, Inc.
|
49
/ 100
| -5.6
| 88.9%
| -450.2%
| -60.8%
| -€781.82K
|
| Selecta Biosciences, Inc.
|
50
/ 100
| -2.4
| 81.3%
| 123.1%
| -14.7%
| -€768.03K
|
| G&E Herbal Biotechnology Co., Ltd.
|
50
/ 100
| 23
| 84.1%
| 51.3%
| 13.3%
| €94.91K
|
| India Globalization Capital, Inc.
|
50
/ 100
| -3.9
| 46.0%
| -524.1%
| -79.8%
| -€81.22K
|
| Bicycle Therapeutics plc
|
50
/ 100
| -2.4
| 52.5%
| -1,023.4%
| -32.8%
| -€705.14K
|
| Stoke Therapeutics, Inc.
|
45
/ 100
| 15
| 99.0%
| 13.2%
| 11.3%
| €271.93K
|
| Tissue Regenix Group plc
|
50
/ 100
| -0.18
| 48.6%
| -1.1%
| -5.6%
| -€26.35K
|
| BioMarin Pharmaceutical Inc.
|
57
/ 100
| 33
| 81.3%
| 20.0%
| 4.4%
| €94.47K
|
| Catalyst Pharmaceuticals, Inc.
|
56
/ 100
| 15
| 82.4%
| 43.6%
| 21.5%
| €989.14K
|
| Nautilus Biotechnology, Inc.
|
50
/ 100
| -1.5
| 50.0%
| 245.0%
| -31.3%
| -€402.20K
|
| Clinuvel Pharmaceuticals Limited
|
50
/ 100
| 7.1
| 76.8%
| 47.9%
| 26.4%
| €2.56M
|
| Clovis Oncology, Inc.
|
50
/ 100
| 0
| 65.6%
| -209.1%
| -72.6%
| -€523.33K
|
| Destiny Pharma plc
|
50
/ 100
| -0.0024
| 98.1%
| -1,487.4%
| -122.1%
| -€926.95K
|
| Tibet Cheezheng Tibetan Medicine Co., Ltd.
|
50
/ 100
| 21
| 82.5%
| 26.1%
| 9.2%
| €24.05K
|
| Viracta Therapeutics, Inc.
|
50
/ 100
| -0.017
| 55.4%
| -6,397.0%
| -197.1%
| -€1.43M
|
| Marizyme, Inc.
|
50
/ 100
| -0.0018
| -168.9%
| -14,404.3%
| -103.6%
| -€1.45M
|
| Oxurion N.V.
|
50
/ 100
| -0.04
| -118.6%
| -11,780.2%
| -189.0%
| -€855.82K
|
| Avidity Biosciences, Inc.
|
50
/ 100
| -8.9
| 92.4%
| -4,863.3%
| -33.3%
| -€1.00M
|
| Genmab A/S
|
52
/ 100
| 12
| 95.0%
| 34.4%
| 2.8%
| €378.59K
|
| OSE Immunotherapeutics SA
|
50
/ 100
| 8.5
| 98.8%
| 4.9%
| 11.7%
| €225.66K
|
| BiomX Inc.
|
50
/ 100
| -0.3
| 2,696.6%
| -40,002.3%
| -99.5%
| -€624.54K
|
| Moderna, Inc.
|
56
/ 100
| -4.3
| 52.1%
| -107.1%
| -24.2%
| -€429.44K
|
| Public Joint-Stock Company "Human Stem Cells Institute"
|
50
/ 100
| 55
| 66.9%
| 17.6%
| 3.0%
| €0.00
|
| Shanghai Shen Lian Biomedical Corporation
|
50
/ 100
| -117
| 60.4%
| -12.1%
| -1.4%
| -€6.71K
|
| NextCell Pharma AB
|
50
/ 100
| -1.9
| -125.1%
| -409.3%
| -76.2%
| -€151.30K
|
| Invivyd, Inc.
|
50
/ 100
| 2.6
| 93.5%
| 65.7%
| 44.7%
| €338.22K
|
| Biotechnologies Assets SA
|
50
/ 100
| -7
| 89.5%
| -91.3%
| -19.7%
| -€76.77K
|
| Puma Biotechnology, Inc.
|
50
/ 100
| 3.6
| 72.3%
| 19.3%
| 24.9%
| €241.69K
|
| Chabiotech Co.,Ltd.
|
50
/ 100
| -13
| 27.1%
| -6.9%
| -3.3%
| -€172.48K
|
| IRLAB Therapeutics AB (publ)
|
50
/ 100
| -3.5
| -28.6%
| -114.5%
| -88.7%
| -€304.44K
|
| VivoSim Labs, Inc.
|
50
/ 100
| -1.6
| 71.8%
| -8,552.8%
| -16.6%
| -€121.77K
|
| genOway SA
|
50
/ 100
| 13
| 23.1%
| -35.6%
| 6.5%
| €20.35K
|
| Lyka Labs Limited
|
50
/ 100
| 57
| 60.0%
| 13.8%
| 0.0%
| €1.69K
|
| Praxis Precision Medicines, Inc.
|
50
/ 100
| -3.3
| -782.9%
| -3,927.5%
| -68.9%
| -€2.02M
|
| Avid Bioservices, Inc.
|
50
/ 100
| -5.3
| 7.7%
| -13.5%
| -47.0%
| -€351.64K
|
| XOMA Corporation
|
51
/ 100
| -25
| 96.9%
| -32.0%
| -5.3%
| -€788.96K
|
| Inhibrx Biosciences, Inc.
|
50
/ 100
| -1.4
| -38.1%
| -11,002.1%
| -87.4%
| -€852.97K
|
| Frequency Therapeutics, Inc.
|
50
/ 100
| -1.2
| 0.0%
| -1,949.0%
| -62.0%
| -€2.09M
|
| ERYTECH Pharma S.A.
|
50
/ 100
| -0.025
| -587.3%
| -1,605.3%
| -87.8%
| -€1.44M
|
| Tango Therapeutics, Inc.
|
50
/ 100
| -5.1
| 18.1%
| -165.9%
| -47.8%
| -€556.40K
|
| Stayble Therapeutics AB (publ)
|
50
/ 100
| -3.1
| 100.0%
| -26,036.4%
| -76.1%
| -€423.26K
|
| RepliCel Life Sciences Inc.
|
50
/ 100
| 1.4
| 99.9%
| -231.8%
| 445.4%
| €0.00
|
| Inter Pharma Public Company Limited
|
50
/ 100
| 26
| 39.1%
| 6.1%
| 2.3%
| €0.00
|
| Novavax, Inc.
|
50
/ 100
| 3.2
| 87.9%
| 34.3%
| 31.6%
| €381.07K
|
| Harpoon Therapeutics, Inc.
|
50
/ 100
| -28
| 92.5%
| -104.8%
| -64.9%
| -€588.49K
|
| Northwest Biotherapeutics, Inc.
|
50
/ 100
| -4.2
| 78.7%
| -6,927.3%
| -295.3%
| -€3.10M
|
| Aptahem AB (publ)
|
50
/ 100
| -2.9
| 411.3%
| -1,177.0%
| -11.1%
| -€169.57K
|
| Revance Therapeutics, Inc.
|
50
/ 100
| -2.1
| 70.7%
| -67.2%
| -39.3%
| -€260.76K
|
| AVEO Pharmaceuticals, Inc.
|
50
/ 100
| 0
| 87.4%
| -26.9%
| -40.0%
| -€304.98K
|
| Alterity Therapeutics Limited
|
50
/ 100
| -3.2
| 97.1%
| -403.8%
| -67.9%
| -€1.78M
|
| Geron Corporation
|
50
/ 100
| -11
| 98.0%
| -47.1%
| -15.9%
| -€329.75K
|
| Veracyte, Inc.
|
52
/ 100
| 72
| 67.2%
| 5.0%
| 2.2%
| €31.57K
|
| Nanobiotix S.A.
|
50
/ 100
| -1.9
| 108.6%
| -400.3%
| -159.9%
| -€998.44K
|
| NKGen Biotech, Inc. Warrants
|
50
/ 100
| -0.033
| 0.0%
| -4,135.9%
| -184,525.0%
| -€603.13K
|
| Rani Therapeutics Holdings, Inc.
|
50
/ 100
| -1.2
| 50.8%
| -4,351.5%
| -279.3%
| -€231.37K
|
| BioLight Life Sciences Ltd.
|
50
/ 100
| -4.4
| 9.6%
| -7,616.2%
| -75.9%
| -€1.35M
|
| Simris Alg AB (publ)
|
50
/ 100
| -4
| 69.9%
| -1,155.1%
| -20.3%
| -€382.87K
|
| Caliway Biopharmaceuticals Co., Ltd.
|
50
/ 100
| -41
| 52.5%
| -1,145.5%
| -6.5%
| €0.00
|
| NKGen Biotech, Inc. Common Stock
|
50
/ 100
| -0.4
| 0.0%
| -4,135.9%
| -184,525.0%
| -€603.13K
|
| Xencor, Inc.
|
50
/ 100
| -4.9
| 100.0%
| -71.6%
| -16.0%
| -€476.19K
|
| Macrogen, Inc.
|
50
/ 100
| -43K
| 33.5%
| -5.7%
| -2.3%
| -€8.44K
|
| ONE Bio Corp.
|
50
/ 100
| 0.00018
| 43.9%
| 27.5%
| 11.3%
| €22.43K
|
| Poltreg S.A.
|
50
/ 100
| -6.7
| -2,260.4%
| -10,123.6%
| -27.9%
| -€174.62K
|
| Adlai Nortye Ltd. American Depositary Shares
|
50
/ 100
| -0.3
| 100.0%
| -996.4%
| -50.2%
| -€377.14K
|
| Poxel S.A.
|
50
/ 100
| -0.61
| -460.0%
| -539.1%
| -1,079.9%
| -€10.06M
|
| Genocea Biosciences, Inc.
|
50
/ 100
| 0
| 100.0%
| -20,525.2%
| -101.2%
| -€455.26K
|
| Clarity Pharmaceuticals Ltd
|
50
/ 100
| -7
| 99.7%
| -653.4%
| -105.4%
| -€1.22M
|
| Hvsen Biotechnology Co., Ltd.
|
50
/ 100
| 30
| 21.4%
| 10.8%
| 5.0%
| €16.92K
|
| Phathom Pharmaceuticals, Inc.
|
50
/ 100
| -3.5
| 87.2%
| -145.0%
| -75.0%
| -€362.16K
|
| Coya Therapeutics, Inc.
|
50
/ 100
| -0.015
| 96.8%
| -1,518,643.2%
| -18.3%
| -€655.21M
|
| Senti Biosciences, Inc.
|
50
/ 100
| -1.3
| 24.8%
| -1,102.7%
| -85.1%
| -€1.47M
|
| Level Biotechnology Inc.
|
50
/ 100
| 16
| 32.6%
| 9.5%
| 8.1%
| €14.35K
|
| Nurix Therapeutics, Inc.
|
50
/ 100
| -3.7
| 36.4%
| -319.3%
| -46.9%
| -€734.36K
|
| Tiansheng Pharmaceutical Group Co., Ltd.
|
50
/ 100
| -15
| 50.2%
| -22.5%
| -3.6%
| -€9.08K
|
| Navidea Biopharmaceuticals, Inc.
|
50
/ 100
| -0.059
| -19,972.8%
| -1,668,791.0%
| -20.7%
| -€92.23K
|
| Akebia Therapeutics, Inc.
|
50
/ 100
| -26
| 74.4%
| 0.4%
| -10.6%
| -€172.95K
|
| MEDINET Co., Ltd.
|
50
/ 100
| -5.5
| 17.7%
| -192.2%
| -22.1%
| -€84.24K
|
| CellSource Co., Ltd.
|
50
/ 100
| 60
| 59.6%
| 5.0%
| 3.5%
| €8.82K
|
| Bioasis Technologies Inc.
|
50
/ 100
| -0.4
| 100.0%
| -469.2%
| 0.0%
| €0.00
|
| Century Therapeutics, Inc.
|
50
/ 100
| -2.2
| 97.2%
| -28.5%
| -8.2%
| -€142.67K
|
| Blue Jet Healthcare Limited
|
50
/ 100
| 43
| 51.7%
| 38.5%
| 0.0%
| €76.44K
|
| Zogenix, Inc.
|
50
/ 100
| 0
| 94.1%
| -259.5%
| -48.5%
| -€596.70K
|
| NeoCore Technology Co., Ltd.
|
50
/ 100
| -75
| 32.9%
| -40.8%
| -3.2%
| €0.00
|
| GeoVax Labs, Inc.
|
50
/ 100
| -0.69
| 98.5%
| -1,021.1%
| -376.0%
| -€1.28M
|
| MaaT Pharma SA
|
50
/ 100
| -1.6
| 46.2%
| -869.9%
| -113.1%
| -€936.80K
|
| Solarvest BioEnergy Inc.
|
50
/ 100
| -0.6
| -82.8%
| 3,805.9%
| -180.1%
| €0.00
|
| GNI Group Ltd.
|
50
/ 100
| -701
| 71.7%
| -4.6%
| -0.4%
| -€1.70K
|
| OliX Pharmaceuticals,Inc
|
50
/ 100
| -21
| 82.7%
| -401.5%
| -59.3%
| -€366.87K
|
| Adaptive Biotechnologies Corporation
|
57
/ 100
| -20
| 71.8%
| -30.9%
| -16.2%
| -€110.35K
|
| Y-mAbs Therapeutics, Inc.
|
50
/ 100
| -9.9
| 81.6%
| -31.2%
| -19.0%
| -€183.34K
|
| Oxford BioDynamics Plc
|
50
/ 100
| -0.003
| -917.5%
| -1,613.7%
| -178.2%
| -€531.36K
|
| Chinook Therapeutics, Inc.
|
50
/ 100
| -11
| 70.5%
| -4,302.1%
| -49.8%
| -€975.11K
|
| Synovics Pharmaceuticals, Inc.
|
50
/ 100
| -0.00059
| 23.4%
| -22.6%
| -26.9%
| -€27.92K
|
| Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
|
50
/ 100
| -283
| 57.8%
| -20.8%
| -2.1%
| -€9.55K
|
| Botanix Pharmaceuticals Limited
|
50
/ 100
| -6.4
| -25.3%
| -1,210.7%
| -77.7%
| -€5.19M
|
| Allogene Therapeutics, Inc.
|
50
/ 100
| -1.3
| 28,813.6%
| 1,155,790.9%
| -50.3%
| -€899.41K
|
| Midatech Pharma plc
|
50
/ 100
| -0.000039
| -8,531.3%
| -20,463.9%
| -88.0%
| -€745.83K
|
| Beijing Konruns Pharmaceutical Co.,Ltd.
|
50
/ 100
| 97
| 89.9%
| 6.7%
| 1.4%
| €9.82K
|
| Barinthus Biotherapeutics plc
|
50
/ 100
| -0.72
| 77.4%
| 225.3%
| -41.6%
| -€440.14K
|
| Black Diamond Therapeutics, Inc.
|
50
/ 100
| 6.3
| 99.9%
| 16.9%
| 13.6%
| €768.55K
|
| DNAPrint Genomics, Inc.
|
50
/ 100
| -0.00014
| 23.1%
| 326.5%
| -146.2%
| -€162.69K
|
| Carna Biosciences, Inc.
|
50
/ 100
| -3.2
| 71.0%
| -355.4%
| -130.9%
| -€187.42K
|
| Surrozen, Inc.
|
50
/ 100
| -0.82
| 87.3%
| -1,055.6%
| -92.4%
| -€1.86M
|
| Eiger BioPharmaceuticals, Inc.
|
50
/ 100
| -0.17
| 95.9%
| -455.1%
| -193.1%
| -€1.15M
|
| Global Blood Therapeutics, Inc.
|
50
/ 100
| 0
| 98.1%
| -126.6%
| -37.5%
| -€612.76K
|
| XTL Biopharmaceuticals Ltd.
|
50
/ 100
| -9.9
| 26.4%
| -481.6%
| -12.0%
| -€88.12K
|
| Organovo Holdings, Inc.
|
50
/ 100
| -1.6
| 71.8%
| -8,552.8%
| -16.6%
| -€121.77K
|
| Novo Nordisk A/S
|
56
/ 100
| 21
| 83.9%
| 45.8%
| 23.0%
| €192.12K
|
| Tonix Pharmaceuticals Holding Corp.
|
50
/ 100
| -7.6
| 29.3%
| -838.0%
| -19.4%
| -€384.73K
|
| MedinCell S.A.
|
50
/ 100
| -9
| 113.6%
| -183.7%
| -98.3%
| -€441.75K
|
| Corline Biomedical AB
|
50
/ 100
| -10
| 85.8%
| -292.3%
| -27.2%
| -€164.99K
|
| CSL Limited
|
50
/ 100
| 7.2
| 48.8%
| 22.6%
| 18.0%
| €181.72K
|
| CDT Equity Inc.
|
50
/ 100
| 0.011
| 42.4%
| 2.7%
| 5.0%
| €23.91M
|
| Voronoi, Inc.
|
50
/ 100
| -92
| 100.0%
| -1,335.2%
| -83.5%
| -€193.09K
|
| Kintara Therapeutics, Inc.
|
50
/ 100
| -0.57
| 50.0%
| 8,211.8%
| -60.3%
| -€17.91M
|
| Nanologica AB (publ)
|
50
/ 100
| -1.8
| 9.9%
| -265.0%
| -53.5%
| -€343.72K
|
| Oncopeptides AB (publ)
|
50
/ 100
| -1.2
| 96.6%
| -512.4%
| -195.8%
| -€305.01K
|
| Genus plc
|
50
/ 100
| 0.48
| 100.0%
| 3.6%
| 3.0%
| €8.89K
|
| 4sc AG
|
50
/ 100
| -18
| 64.1%
| -2,771.7%
| -87.6%
| -€249.61K
|
| BioStem Technologies, Inc.
|
50
/ 100
| 8.7
| 97.0%
| 7.5%
| 23.3%
| €11.27M
|
| Fusion Antibodies plc
|
50
/ 100
| -0.02
| 5.3%
| -131.3%
| -297.7%
| -€166.81K
|
| Outlook Therapeutics, Inc.
|
50
/ 100
| -1.8
| 70.8%
| -4,824.5%
| -194.0%
| -€1.62M
|
| BTC Health Limited
|
50
/ 100
| 3.4
| 67.5%
| 1,817.2%
| 53.8%
| €2.87M
|
| NetScientific plc
|
50
/ 100
| -0.028
| 62.7%
| -209.1%
| -29.2%
| -€224.77K
|
| Citius Pharmaceuticals, Inc.
|
50
/ 100
| -0.25
| -26.5%
| -19,161.7%
| -32.0%
| -€1.52M
|
| EV Biologics, Inc.
|
50
/ 100
| -2.1
| 77.4%
| -61.6%
| -62.3%
| -€895.17
|
| Arch Biopartners Inc.
|
50
/ 100
| -51
| 0.0%
| 523.9%
| -895.7%
| €0.00
|
| Grace Therapeutics, Inc.
|
50
/ 100
| -4.2
| -12.5%
| -185,100.0%
| -14.8%
| -€2.21M
|
| Ribomic Inc.
|
50
/ 100
| -4
| 100.0%
| -49,861.9%
| -32.0%
| -€234.19K
|
| Mesoblast Limited
|
50
/ 100
| -9.9
| -398.0%
| -1,503.6%
| -15.8%
| -€1.21M
|
| Arecor Therapeutics plc
|
50
/ 100
| -0.0098
| 39.5%
| -149.8%
| -319.4%
| -€383.49K
|
| C4X Discovery Holdings plc
|
50
/ 100
| 0.1
| 97.4%
| -2.6%
| 11.6%
| €71.03K
|
| Soiken Holdings Inc.
|
50
/ 100
| -19
| 50.3%
| -3.5%
| -3.5%
| -€14.56K
|
| Entia Biosciences, Inc.
|
50
/ 100
| -0.0046
| 65.5%
| -439.7%
| -335.3%
| -€210.59K
|
| Generation Bio Co.
|
50
/ 100
| -0.36
| 100.0%
| -381.4%
| -40.4%
| -€540.32K
|
| Applied Therapeutics, Inc.
|
50
/ 100
| -0.78
| -76.9%
| -92,056.2%
| -181.4%
| -€1.66M
|
| Arcutis Biotherapeutics, Inc.
|
50
/ 100
| -37
| 90.0%
| -12.0%
| -11.9%
| -€111.20K
|
| BioRestorative Therapies, Inc.
|
50
/ 100
| -1.3
| 94.5%
| -2,162.9%
| -125.9%
| -€836.44K
|
| Diamyd Medical AB (publ)
|
50
/ 100
| -7.7
| -2,958.9%
| -138,764.3%
| -43.7%
| -€531.69K
|
| Crinetics Pharmaceuticals, Inc.
|
49
/ 100
| -8.2
| 31.1%
| -30,392.2%
| -28.7%
| -€726.13K
|
| Marinus Pharmaceuticals, Inc.
|
50
/ 100
| -0.22
| 88.9%
| -395.9%
| -220.8%
| -€730.55K
|
| Chunghwa Chemical Synthesis & Biotech Co., Ltd.
|
50
/ 100
| -32
| 21.3%
| -8.5%
| -1.5%
| -€7.76K
|
| Ulisse Biomed S.p.A.
|
50
/ 100
| -3.2
| -360.4%
| -1,074.5%
| -19.9%
| -€782.47K
|
| Anterogen.Co.,Ltd.
|
50
/ 100
| -105
| 36.1%
| -48.2%
| -2.2%
| -€33.34K
|
| BioAtla, Inc.
|
50
/ 100
| -0.45
| 99.0%
| -579.8%
| -219.4%
| -€837.11K
|
| BioArctic AB (publ)
|
50
/ 100
| 16
| 97.2%
| 63.2%
| 45.8%
| €910.67K
|
| Ardelyx, Inc.
|
50
/ 100
| -16
| 89.5%
| -9.5%
| -11.6%
| -€122.83K
|
| Bionomics Limited
|
50
/ 100
| 0.87
| 2.4%
| 30.6%
| 28.4%
| €936.32K
|
| MEDIPOST Co., Ltd.
|
50
/ 100
| -5.7K
| 61.9%
| -78.3%
| -18.1%
| €0.00
|
| Meribank Biotech Co., Ltd
|
50
/ 100
| -16
| 50.3%
| -18.3%
| -4.0%
| €0.00
|
| Halberd Corporation
|
50
/ 100
| -11
| 9.6%
| -4,739.9%
| -941.6%
| -€27.28K
|
| SynCore Biotechnology Co.,Ltd
|
50
/ 100
| -18
| 58.2%
| -217.0%
| -18.4%
| -€36.27K
|
| Xiangxue Pharmaceutical Co.,Ltd.
|
50
/ 100
| -6
| 20.5%
| -54.1%
| -12.9%
| -€43.95K
|
| Orgenesis Inc.
|
50
/ 100
| -0.25
| 139.3%
| 724.9%
| -148.0%
| -€258.23K
|
| FibroGen, Inc.
|
50
/ 100
| -15
| 79.4%
| 185.9%
| -1.2%
| -€7.88K
|
| Medigen Vaccine Biologics Corporation
|
50
/ 100
| -111
| 61.3%
| -20.8%
| -3.4%
| -€37.79K
|
| Assure Tech (Hangzhou) Co., Ltd.
|
50
/ 100
| 34
| 38.3%
| 28.0%
| 2.5%
| €22.27K
|
| Hualan Biological Bacterin Inc.
|
50
/ 100
| 50
| 81.0%
| 17.6%
| 2.9%
| €32.63K
|
| Pulmatrix, Inc.
|
50
/ 100
| -4.9
| 100.0%
| -207,100.0%
| -124.8%
| -€2.67M
|
| CAMP4 Therapeutics Corporation
|
50
/ 100
| -0.65
| 86.1%
| -1,756.7%
| -99.2%
| -€793.65K
|
| Medigen Biotechnology Corp.
|
50
/ 100
| -67
| 58.3%
| 2.6%
| -1.0%
| €0.00
|
| Coeptis Therapeutics Holdings, Inc.
|
50
/ 100
| -2.9
| 31.7%
| -605.8%
| -85.1%
| -€2.22M
|
| Cardio Diagnostics Holdings, Inc.
|
50
/ 100
| -1.2
| -357.0%
| -31,961.0%
| -60.1%
| -€412.51K
|
| Neith Corporation
|
50
/ 100
| -1.5K
| 81.9%
| -7.4%
| -0.4%
| -€414.63
|
| Abivax S.A.
|
50
/ 100
| -1.4
| 72.2%
| -2,799.6%
| -238.0%
| -€4.13M
|
| American Oriental Bioengineering, Inc.
|
50
/ 100
| -0.00000041
| 32.6%
| -64.3%
| -21.3%
| -€21.00K
|
| America Great Health
|
50
/ 100
| -9.1
| 66.1%
| -181.9%
| -347.7%
| -€159.32K
|
| Health Sciences Group, Inc.
|
50
/ 100
| -0.05
| 25.6%
| -3,500.5%
| -101.7%
| -€1.61M
|
| Syros Pharmaceuticals, Inc.
|
50
/ 100
| -0.008
| -228.8%
| -28,892.2%
| -115.1%
| -€1.23M
|
| Genexine, Inc.
|
50
/ 100
| -3.1
| -135.3%
| -2,248.9%
| -22.1%
| -€501.34K
|
| Financière de Tubize SA
|
50
/ 100
| 31
| -280.5%
| -481.3%
| 9.4%
| €60.92M
|
| Liquidia Corporation
|
45
/ 100
| -15
| 92.7%
| -155.0%
| -29.1%
| -€405.12K
|
| Dna Group (T.R.) Ltd
|
50
/ 100
| 903
| 100.0%
| 77.1%
| 0.5%
| €10.62K
|
| NanHua Bio-medicine Co., Ltd
|
50
/ 100
| -465
| 64.2%
| -14.3%
| -0.7%
| -€1.99K
|
| Statera Biopharma, Inc.
|
50
/ 100
| -0.000075
| 70.3%
| -2,391.7%
| -748.5%
| -€1.78M
|
| CTI BioPharma Corp.
|
50
/ 100
| -16
| 94.1%
| -71.2%
| -68.6%
| -€520.29K
|
| PolarityTE, Inc.
|
50
/ 100
| 0.1
| -14,053.4%
| -25,071.2%
| 96.4%
| €355.60K
|
| BioCryst Pharmaceuticals, Inc.
|
51
/ 100
| -253
| 97.4%
| 12.7%
| -2.0%
| -€12.99K
|
| Beijing Hotgen Biotech Co., Ltd.
|
50
/ 100
| -66
| 58.6%
| -47.3%
| -6.8%
| -€25.75K
|
| TFF Pharmaceuticals, Inc.
|
50
/ 100
| -0.016
| 76.9%
| -1,068.2%
| -261.7%
| -€836.40K
|
| Recursion Pharmaceuticals, Inc.
|
50
/ 100
| -3
| -93.8%
| -1,662.1%
| -51.1%
| -€767.42K
|
| Kane Biotech Inc.
|
50
/ 100
| -4.7
| 21.9%
| -170.4%
| -51.0%
| €0.00
|
| Absci Corporation
|
50
/ 100
| -3.3
| -36.0%
| -4,229.1%
| -46.8%
| -€630.32K
|
| Heidelberg Pharma AG
|
50
/ 100
| -9.3
| 76.9%
| -640.2%
| -37.3%
| -€221.98K
|
| Bolt Biotherapeutics, Inc.
|
51
/ 100
| -5.2
| 100.0%
| -1,312.3%
| -67.2%
| -€836.77K
|
| Aeterna Zentaris Inc.
|
50
/ 100
| -0.75
| 35.1%
| -844.3%
| -33.9%
| -€1.21M
|
| PlantArc Bio Ltd.
|
50
/ 100
| -5.3
| 52.8%
| -76.5%
| -64.5%
| -€103.33K
|
| MiMedx Group, Inc.
|
50
/ 100
| 23
| 82.0%
| 13.7%
| 12.8%
| €41.85K
|
| Novan, Inc.
|
50
/ 100
| 2.6
| 65.8%
| -144.2%
| 1.3%
| €9.52K
|
| Pharma Mar, S.A.
|
50
/ 100
| 35
| 95.0%
| 16.6%
| 12.1%
| €84.02K
|
| Recce Pharmaceuticals Ltd
|
50
/ 100
| -2.2
| -9.3%
| -454.3%
| -314.9%
| €0.00
|
| Captor Therapeutics Spolka Akcyjna
|
50
/ 100
| -4.8
| 39.3%
| -385.4%
| -71.7%
| -€88.87K
|
| IGM Biosciences, Inc.
|
50
/ 100
| -1.4
| 98.1%
| -19.2%
| -49.9%
| -€307.41K
|
| Biomm S.A.
|
50
/ 100
| -16
| 12.5%
| -46.3%
| -16.1%
| -€82.06K
|
| ARS Pharmaceuticals, Inc.
|
50
/ 100
| -29
| 78.0%
| -52.8%
| -15.3%
| -€265.80K
|
| Nanosynth Group Plc
|
50
/ 100
| 0
| 41.1%
| -299.9%
| -64.6%
| -€69.15K
|
| ImmuCell Corporation
|
50
/ 100
| 0.039
| 41.6%
| 6.7%
| 3,097.8%
| €18.00M
|
| Paradigm Biopharmaceuticals Limited
|
50
/ 100
| -1.5
| -110.9%
| -74,636.4%
| -315.1%
| €0.00
|
| Arch Therapeutics, Inc.
|
50
/ 100
| -0.000036
| 39.6%
| -3,186.9%
| -877.4%
| -€1.32M
|
| Hubei Goto Biopharm Co.,Ltd.
|
50
/ 100
| -64
| 21.6%
| -7.7%
| -1.1%
| -€6.47K
|
| Mereo BioPharma Group plc
|
50
/ 100
| -8.5
| 73.6%
| -9,269.8%
| -79.1%
| -€1.18M
|
| BioInvent International AB (publ)
|
50
/ 100
| -8.4
| 100.0%
| -126.5%
| -31.8%
| -€225.96K
|
| Soligenix, Inc.
|
50
/ 100
| -0.83
| -11.1%
| -183,452.1%
| -128.6%
| -€454.00K
|
| Pluri Inc.
|
50
/ 100
| -1.7
| 46.2%
| -2,155.1%
| 0.0%
| -€169.19K
|
| iNtRON Biotechnology, Inc.
|
50
/ 100
| -23
| 53.1%
| -131.6%
| -7.3%
| -€45.74K
|
| Intervacc AB (publ)
|
50
/ 100
| -4.9
| -5.5%
| -401.0%
| -19.7%
| -€433.58K
|
| Peptron, Inc.
|
50
/ 100
| -263
| 53.0%
| -338.8%
| -10.5%
| -€105.42K
|
| Braxia Scientific Corp.
|
50
/ 100
| -0.15
| 14.7%
| -200.9%
| -412.2%
| €0.00
|
| Ryvu Therapeutics S.A.
|
50
/ 100
| -5.8
| 74.2%
| -189.0%
| -42.9%
| -€86.88K
|
| Tevogen Bio Holdings Inc.
|
50
/ 100
| -3.8
| -23.3%
| -7,879.7%
| -730.8%
| -€1.57M
|
| Evolva Holding SA
|
50
/ 100
| -0.37
| 1,934.8%
| 4,630.8%
| -297.5%
| -€458.14K
|
| Sensorion SA
|
50
/ 100
| -2.3
| 91.3%
| -461.4%
| -70.6%
| -€821.52K
|
| Cerevel Therapeutics Holdings, Inc.
|
50
/ 100
| -18
| 29.1%
| -5,946.8%
| -40.8%
| -€1.11M
|
| Great Novel Therapeutics Biotech & Medicals
|
50
/ 100
| -8.4
| -84.6%
| -7,771.0%
| -30.1%
| -€269.88K
|
| QuiaPEG Pharmaceuticals Holding AB (publ)
|
50
/ 100
| -0.35
| 114.5%
| 1,697.5%
| -212.5%
| -€988.39K
|
| Eusol Biotech Co.,Ltd.
|
50
/ 100
| -13
| -1,350.5%
| -12,050.4%
| -22.2%
| €0.00
|
| Doseology Sciences Inc.
|
50
/ 100
| -5.1
| 3.0%
| -379.1%
| -28.7%
| €0.00
|
| Ocugen, Inc.
|
50
/ 100
| -6
| 100.0%
| -1,165.1%
| -106.2%
| -€514.25K
|
| Intech Biopharm Corporation
|
50
/ 100
| -9.2
| -85.2%
| -260.6%
| -11.8%
| -€98.46K
|
| Dianthus Therapeutics, Inc.
|
50
/ 100
| -5.1
| 98.0%
| -2,676.6%
| -35.2%
| -€1.26M
|
| Staidson (Beijing) BioPharmaceuticals Co., Ltd.
|
50
/ 100
| -99
| 77.9%
| -24.3%
| -13.1%
| -€36.34K
|
| Harmony Biosciences Holdings, Inc.
|
50
/ 100
| 11
| 77.7%
| 27.3%
| 15.4%
| €594.44K
|
| Vertex Pharmaceuticals Incorporated
|
53
/ 100
| 32
| 86.3%
| 34.1%
| 14.8%
| €516.92K
|
| Trans Genic Inc.
|
50
/ 100
| -13
| 17.4%
| -0.7%
| -2.4%
| -€5.81K
|
| Zai Lab Limited
|
51
/ 100
| -23
| 62.4%
| -57.7%
| -18.3%
| -€97.56K
|
| Metagenomi, Inc. Common Stock
|
50
/ 100
| -0.62
| 100.0%
| -271.9%
| -32.0%
| -€370.04K
|
| Panion & Bf Biotech Inc.
|
50
/ 100
| 52
| 52.5%
| 12.3%
| 4.0%
| €10.86K
|
| Shanghai Allist Pharmaceuticals Co., Ltd.
|
50
/ 100
| 24
| 96.6%
| 49.8%
| 26.2%
| €212.20K
|
| Marinomed Biotech AG
|
50
/ 100
| -2.5
| -29.1%
| -84.9%
| -124.7%
| -€392.14K
|
| SillaJen, Inc.
|
50
/ 100
| -18
| 29.1%
| -414.3%
| -19.2%
| -€343.40K
|
| Zealand Pharma A/S
|
50
/ 100
| 5.1
| 100.1%
| 78.8%
| 38.9%
| €2.32M
|
| Theriva Biologics, Inc.
|
50
/ 100
| -0.15
| 32.5%
| -13,547.4%
| -82.5%
| -€1.27M
|
| co.don AG
|
50
/ 100
| 0
| 91.0%
| -86.5%
| -37.0%
| -€78.75K
|
| Suzhou Zelgen Biopharmaceuticals Co., Ltd.
|
50
/ 100
| -223
| 91.3%
| -22.8%
| -4.8%
| -€20.18K
|
| Panacos Pharmaceuticals, Inc.
|
50
/ 100
| -0.00015
| 100.0%
| 34,568.7%
| -120.2%
| -€748.24K
|
| Xiamen Amoytop Biotech Co., Ltd.
|
50
/ 100
| 31
| 93.3%
| 34.5%
| 29.6%
| €47.65K
|
| Infinity Pharmaceuticals, Inc.
|
50
/ 100
| -0.018
| 39.7%
| -1,636.7%
| -188.0%
| -€1.14M
|
| China Resources Boya Bio-pharmaceutical Group Co., Ltd.
|
50
/ 100
| 45
| 57.1%
| 20.2%
| 3.5%
| €19.19K
|
| Camurus AB (publ)
|
50
/ 100
| 50
| 93.5%
| 37.0%
| 16.2%
| €275.66K
|
| Concord Biotech Limited
|
50
/ 100
| 55
| 67.6%
| 36.0%
| 0.0%
| €24.64K
|
| Prescient Therapeutics Limited
|
50
/ 100
| -2.7
| 100.0%
| -206.5%
| -106.9%
| -€2.96M
|
| iBio, Inc.
|
50
/ 100
| -0.79
| 42.2%
| -4,089.4%
| -31.3%
| -€1.08M
|
| UCB SA
|
50
/ 100
| 17
| 70.1%
| 17.6%
| 9.1%
| €173.66K
|
| Actinogen Medical Limited
|
50
/ 100
| -2.3
| 98.6%
| -187.4%
| -113.5%
| €0.00
|
| Genomics BioSci & Tech. Co.,Ltd.
|
50
/ 100
| -5.7
| 28.7%
| -23.6%
| -23.9%
| €0.00
|
| Gritstone bio, Inc.
|
50
/ 100
| -0.029
| -325.1%
| -8,786.8%
| -93.3%
| -€494.12K
|
| Takara Bio Inc.
|
50
/ 100
| 165
| 58.3%
| 4.6%
| 0.4%
| €1.74K
|
| Relay Therapeutics, Inc.
|
50
/ 100
| -1.9
| 1.3%
| -4,105.6%
| -42.7%
| -€1.03M
|
| CG Oncology, Inc. Common stock
|
50
/ 100
| -23
| 71.7%
| -28,546.1%
| -12.4%
| -€657.97K
|
| Gubra A/S
|
50
/ 100
| 5
| 93.4%
| 75.1%
| 58.4%
| €875.42K
|
| PCI Biotech Holding ASA
|
50
/ 100
| -3
| 100.0%
| -461.5%
| -110.9%
| -€348.52K
|
| Transgene SA
|
50
/ 100
| -2.2
| -702.2%
| -2,392.5%
| -145.6%
| -€414.53K
|
| Trillium Therapeutics Inc.
|
50
/ 100
| 0
| 100.0%
| -161,183.7%
| 24.5%
| €1.69M
|
| Elicera Therapeutics AB (publ)
|
50
/ 100
| -16
| 48.4%
| -3,662.0%
| -38.8%
| -€724.37K
|
| Matinas BioPharma Holdings, Inc.
|
50
/ 100
| -0.27
| -12.9%
| -1,268.4%
| -171.6%
| -€5.61M
|
| Covalon Technologies Ltd.
|
50
/ 100
| 28
| 55.7%
| 4.6%
| 6.6%
| €0.00
|
| Acceleron Pharma Inc.
|
50
/ 100
| 0
| 100.0%
| -226.6%
| -32.3%
| -€700.84K
|
| Genelux Corporation
|
50
/ 100
| -3.3
| -31.6%
| -7,145.4%
| -94.2%
| -€1.09M
|
| Biotest AG
|
50
/ 100
| 45
| 30.8%
| 13.0%
| 1.8%
| €10.58K
|
| Maravai LifeSciences Holdings, Inc.
|
50
/ 100
| -1.7
| 29.1%
| -149.5%
| -21.7%
| -€293.10K
|
| GB Sciences, Inc.
|
50
/ 100
| -0.16
| 100.0%
| -872.7%
| -1,104.5%
| -€447.60K
|
| Adverum Biotechnologies, Inc.
|
47
/ 100
| -0.35
| 425.7%
| 5,492.0%
| -162.4%
| -€864.80K
|
| Synaptogenix, Inc.
|
50
/ 100
| -0.24
| 100.0%
| -165,928.9%
| -144.7%
| -€6.14M
|
| Zhejiang Wecome Pharmaceutical Company Limited
|
50
/ 100
| -10
| 3.5%
| -131.4%
| -14.6%
| -€23.65K
|
| InDex Pharmaceuticals Holding AB (publ)
|
50
/ 100
| -64
| 97.0%
| -51.5%
| -20.1%
| -€644.78K
|
| GenMont Biotech Incorporation
|
50
/ 100
| 110
| 60.1%
| 10.2%
| 1.0%
| €2.91K
|
| Ensysce Biosciences, Inc.
|
50
/ 100
| -0.45
| -15.2%
| -245.9%
| -345.1%
| -€1.34M
|
| Agenus Inc.
|
50
/ 100
| -0.86
| -0.5%
| -86.0%
| -89.4%
| -€449.42K
|
| Adagene Inc.
|
50
/ 100
| -1.3
| -1,088.5%
| -58,950.5%
| -83.3%
| -€344.69K
|
| Biomea Fusion, Inc.
|
50
/ 100
| -1.1
| 26.2%
| -9,434.5%
| -113.2%
| -€899.59K
|
| Daan Gene Co., Ltd.
|
50
/ 100
| -15
| 32.5%
| -104.2%
| -6.2%
| -€34.79K
|
| Dishman Carbogen Amcis Limited
|
50
/ 100
| 42
| 81.6%
| 9.5%
| 0.0%
| €8.77K
|
| Opthea Limited
|
50
/ 100
| -0.66
| -51.2%
| -178,012.3%
| -385.1%
| -€12.56M
|
| LegoChem Biosciences, Inc.
|
50
/ 100
| 2.8M
| 89.2%
| -15.8%
| 0.2%
| €6.29K
|
| Krystal Biotech, Inc.
|
50
/ 100
| 20
| 68.8%
| 42.4%
| 16.0%
| €620.60K
|
| Beijing Scitop Bio-tech Co., Ltd.
|
50
/ 100
| 47
| 55.1%
| 33.3%
| 4.7%
| €37.88K
|
| PharmaEngine, Inc.
|
50
/ 100
| 7.5
| 98.1%
| 81.8%
| 28.5%
| €1.02M
|
| Enimmune corporation
|
50
/ 100
| -4
| -0.9%
| -447.0%
| -76.0%
| €0.00
|
| Lipocine Inc.
|
50
/ 100
| -3.9
| 49.2%
| -132.6%
| -24.3%
| -€241.70K
|
| Shijiazhuang Yiling Pharmaceutical Co., Ltd.
|
50
/ 100
| -88
| 56.9%
| -3.5%
| -2.0%
| -€2.89K
|
| Neonc Technologies Holdings, Inc.
|
50
/ 100
| -4.1
| 100.0%
| -79,297.8%
| -1,610.3%
| -€5.16M
|
| Vanda Pharmaceuticals Inc.
|
51
/ 100
| -3.2
| 0.3%
| -57.1%
| -14.0%
| -€196.31K
|
| NaviFUS Corp.
|
50
/ 100
| -12
| 32.1%
| -351.0%
| -17.1%
| €0.00
|
| Sinphar Pharmaceutical Co.,Ltd.
|
50
/ 100
| 19
| 40.7%
| 11.0%
| 5.1%
| €8.66K
|
| Jiangsu Bioperfectus Technologies Co., Ltd.
|
50
/ 100
| -154
| 59.4%
| -4.9%
| -0.7%
| -€5.59K
|
| EyePoint Pharmaceuticals, Inc.
|
50
/ 100
| -3.5
| 95.1%
| -364.3%
| -58.2%
| -€911.98K
|
| Adynxx, Inc.
|
50
/ 100
| -0.000069
| 0.5%
| -1,065.5%
| -268.2%
| -€1.25M
|
| Cardiff Oncology, Inc.
|
50
/ 100
| -5
| 82.4%
| -9,950.9%
| -67.4%
| -€1.37M
|
| Adimmune Corporation
|
50
/ 100
| -32
| 24.0%
| -34.3%
| -2.7%
| -€11.07K
|
| BRAIN Biotech AG
|
50
/ 100
| -3.8
| 56.6%
| -16.4%
| -16.1%
| -€39.51K
|
| Pharmena S.A.
|
50
/ 100
| -21
| -33.0%
| -325.0%
| -14.6%
| -€28.08K
|
| Aravive, Inc.
|
50
/ 100
| -0.036
| -663.2%
| -372.7%
| -621.9%
| -€3.03M
|
| Medesis Pharma S.A.
|
50
/ 100
| -0.57
| -3,244.9%
| -5,549.2%
| -148.8%
| -€313.41K
|
| Telix Pharmaceuticals Limited
|
50
/ 100
| 131
| 61.6%
| 7.1%
| 5.5%
| €90.58K
|
| Alector, Inc.
|
50
/ 100
| -1.4
| 93.5%
| -165.8%
| -32.3%
| -€565.25K
|
| IBEX Technologies Inc.
|
50
/ 100
| 8.9
| 72.1%
| -17.5%
| 23.1%
| €274.50K
|
| Glow Lifetech Corp.
|
50
/ 100
| -3.2
| 48.0%
| -107.2%
| -71.1%
| €0.00
|
| Redx Pharma Plc
|
50
/ 100
| -0.011
| 98.0%
| -225.2%
| -199.6%
| -€579.17K
|
| Valneva SE
|
50
/ 100
| -6.9
| 49.0%
| -25.6%
| -14.2%
| -€94.03K
|
| Radiopharm Theranostics Limited
|
50
/ 100
| -0.72
| 41.5%
| -561.0%
| -97.9%
| €0.00
|
| Lumos Pharma, Inc.
|
50
/ 100
| -1.1
| 99.0%
| -1,647.6%
| -200.0%
| -€998.60K
|
| Traws Pharma, Inc.
|
50
/ 100
| -0.5
| 99.9%
| -698.1%
| -114.1%
| -€2.55M
|
| AXIM Biotechnologies, Inc.
|
50
/ 100
| -0.51
| -1,179.2%
| -9,326.9%
| -103.2%
| -€493.98K
|
| ChemoCentryx, Inc.
|
50
/ 100
| 0
| 96.5%
| -362.8%
| -30.9%
| -€624.36K
|
| Onconic Therapeutics
|
50
/ 100
| 45
| 100.0%
| 5.8%
| 7.2%
| €21.93K
|
| I-Tech AB
|
50
/ 100
| 28
| 49.5%
| 26.7%
| 21.6%
| €341.32K
|
| Jiangxi Fushine Pharmaceutical Co., Ltd.
|
50
/ 100
| -19
| 11.0%
| -28.8%
| -6.1%
| -€16.87K
|
| CNS Pharmaceuticals, Inc.
|
50
/ 100
| -0.33
| -9.0%
| -496,050.9%
| -106.6%
| -€3.32M
|
| Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
|
50
/ 100
| -160
| 14.3%
| -24.9%
| -6.5%
| -€25.96K
|
| Quantum Genomics SA
|
50
/ 100
| -0.16
| -3,531.4%
| -4,019.1%
| -833.1%
| -€10.40M
|
| Gossamer Bio, Inc.
|
50
/ 100
| -1.9
| 100.0%
| -365.1%
| -74.8%
| -€930.46K
|
| SeaStar Medical Holding Corporation
|
50
/ 100
| -0.94
| 95.3%
| -1,580.5%
| -88.0%
| -€617.08K
|
| Zhejiang Jolly Pharmaceutical Co.,LTD
|
50
/ 100
| 21
| 61.3%
| 25.7%
| 12.7%
| €26.44K
|
| NeurAxis, Inc.
|
50
/ 100
| -3.3
| 84.8%
| -221.6%
| -101.2%
| -€293.04K
|
| Omega Therapeutics, Inc.
|
50
/ 100
| -0.11
| -59.8%
| -916.0%
| -47.9%
| -€674.33K
|
| Evaxion Biotech A/S
|
50
/ 100
| -0.34
| 100.0%
| -438.5%
| -53.4%
| -€223.47K
|
| Nanjing Vazyme Biotech Co., Ltd.
|
50
/ 100
| -295
| 69.1%
| -5.2%
| -0.6%
| -€1.32K
|
| 3D Global Biotech Inc.
|
50
/ 100
| 33
| 66.0%
| 24.2%
| 9.9%
| €66.81K
|
| Oxford Biomedica plc
|
50
/ 100
| -0.02
| 41.1%
| -80.2%
| -82.8%
| -€237.82K
|
| Shanghai ZJ Bio-Tech Co., Ltd.
|
50
/ 100
| -20
| 53.1%
| -123.0%
| -4.3%
| -€65.00K
|
| Blueprint Medicines Corporation
|
47
/ 100
| -53
| 95.8%
| -31.0%
| -13.0%
| -€195.92K
|
| Adocia SA
|
50
/ 100
| -2.2
| -158.6%
| -158.0%
| -112.8%
| -€401.09K
|
| Lineage Cell Therapeutics, Inc.
|
50
/ 100
| -3.9
| 97.6%
| -322.8%
| -45.1%
| -€501.44K
|
| Physiomics Plc
|
50
/ 100
| -0.012
| -104.5%
| -106.3%
| -207.2%
| -€112.84K
|
| Fluicell AB (publ)
|
50
/ 100
| -2
| 105.6%
| -473.2%
| -42.6%
| -€73.46K
|
| Aligos Therapeutics, Inc.
|
50
/ 100
| -0.63
| 70.7%
| -2,473.3%
| -55.1%
| -€909.28K
|
| Chengdu Kanghua Biological Products Co., Ltd.
|
50
/ 100
| 38
| 93.4%
| 20.6%
| 5.4%
| €40.45K
|
| Cabio Biotech (Wuhan) Co., Ltd.
|
50
/ 100
| 26
| 47.4%
| 28.4%
| 8.9%
| €35.29K
|
| Immutep Limited
|
50
/ 100
| -3.6
| -1,058.6%
| -2,414.2%
| -66.3%
| -€3.12M
|
| Kineta, Inc.
|
50
/ 100
| -0.92
| 162.9%
| -159.8%
| -914.3%
| -€600.44K
|
| Kura Oncology, Inc.
|
50
/ 100
| -2.7
| 79.6%
| -230.5%
| -33.4%
| -€969.20K
|
| Core One Labs Inc.
|
50
/ 100
| -0.47
| 89.2%
| -2,567.6%
| -195.1%
| €0.00
|
| Nyrada Inc.
|
50
/ 100
| -6.4
| 9.7%
| -283.5%
| -117.7%
| €0.00
|
| H-CYTE, Inc.
|
50
/ 100
| -0.048
| 120.9%
| 1,249.5%
| -3,734.9%
| -€5.60M
|
| Race Oncology Limited
|
50
/ 100
| -11
| 84.6%
| -212.5%
| -106.4%
| €0.00
|
| Clearside Biomedical, Inc.
|
50
/ 100
| -2.3
| 88.5%
| -524.6%
| -180.7%
| -€743.03K
|
| Bioton S.a.
|
50
/ 100
| -34
| 28.8%
| 1.2%
| -1.4%
| -€6.81K
|
| Carmell Therapeutics Corporation
|
50
/ 100
| -0.078
| 57.5%
| -550.6%
| -193.2%
| -€684.98K
|
| Neon Bloom, Inc.
|
50
/ 100
| -0.97
| 17.1%
| 2.2%
| -234.4%
| -€930.97K
|
| Jinyu Bio-technology Co., Ltd.
|
50
/ 100
| 84
| 52.2%
| 5.6%
| 1.5%
| €7.39K
|
| Generex Biotechnology Corporation
|
50
/ 100
| 0
| 48.2%
| -4,952.5%
| -8.6%
| -€224.85K
|
| Lytix Biopharma AS
|
50
/ 100
| -7.1
| 100.0%
| -12,215.0%
| -65.9%
| -€1.03M
|
| Fortrea Holdings Inc.
|
50
/ 100
| -0.48
| 17.2%
| -21.8%
| -37.1%
| -€58.26K
|
| KalVista Pharmaceuticals, Inc.
|
49
/ 100
| -3.3
| 74.3%
| -14,220.8%
| -94.2%
| -€1.16M
|
| Aurisco Pharmaceutical Co.,Ltd.
|
50
/ 100
| 22
| 60.0%
| 29.7%
| 10.3%
| €32.01K
|
| Shanghai RAAS Blood Products Co., Ltd.
|
50
/ 100
| 25
| 37.9%
| 26.1%
| 4.8%
| €66.18K
|
| Greenyn Biotechnology Co., Ltd
|
50
/ 100
| 14
| 48.2%
| 20.8%
| 7.8%
| €0.00
|
| Caris Life Sciences, Inc.
|
50
/ 100
| -16
| 54.8%
| 15.8%
| -8.9%
| -€41.36K
|
| Syndax Pharmaceuticals, Inc.
|
49
/ 100
| -3
| 96.2%
| -275.1%
| -56.5%
| -€990.12K
|
| Synbio Tech Inc.
|
50
/ 100
| 21
| 54.5%
| 21.6%
| 6.6%
| €0.00
|
| Oxford Nanopore Technologies plc
|
50
/ 100
| -0.043
| 55.4%
| -89.2%
| -39.7%
| -€220.48K
|
| AcouSort AB (publ)
|
50
/ 100
| -5.2
| 99.7%
| -233.0%
| -51.2%
| -€72.39K
|
| Epizyme, Inc.
|
50
/ 100
| 0
| 75.6%
| -354.6%
| -80.9%
| -€733.47K
|
| Alumis Inc. Common Stock
|
50
/ 100
| -2.5
| 100.0%
| -2,189.4%
| -37.2%
| -€1.16M
|
| GeneOne Life Science, Inc.
|
50
/ 100
| -4.6
| -33.5%
| -113.8%
| -39.9%
| -€642.40K
|
| Island Pharmaceuticals Limited
|
50
/ 100
| -7
| -239.0%
| -1,135.6%
| -90.5%
| €0.00
|
| Seer, Inc.
|
50
/ 100
| -1.6
| 49.5%
| -551.6%
| -25.6%
| -€527.88K
|
| Baudax Bio, Inc.
|
50
/ 100
| -0.000061
| -1,539.3%
| -6,781.9%
| -34.8%
| -€682.02K
|
| Aldeyra Therapeutics, Inc.
|
50
/ 100
| -3.5
| -0.4%
| -21,802.1%
| -59.6%
| -€4.83M
|
| Patrys Limited
|
50
/ 100
| -0.31
| 100.0%
| -286.6%
| -376.8%
| -€248.92K
|
| WuXi Biologics (Cayman) Inc.
|
50
/ 100
| 107
| 40.8%
| 25.1%
| 11.3%
| €65.92K
|
| Haisco Pharmaceutical Group Co., Ltd.
|
50
/ 100
| 173
| 72.6%
| 8.3%
| 4.3%
| €7.03K
|
| Alfavision Overseas (India) Limited
|
50
/ 100
| 198
| 14.9%
| 5.1%
| 0.0%
| €1.48K
|
| Molecure S.A.
|
50
/ 100
| -4.3
| -23,697.6%
| -219,447.5%
| -27.6%
| -€68.67K
|
| SinoMab BioScience Limited
|
50
/ 100
| -7.6
| 172.3%
| 16,506.6%
| -47.6%
| -€439.54K
|
| Reata Pharmaceuticals, Inc.
|
50
/ 100
| -82
| 96.5%
| -243.8%
| -15.9%
| -€213.98K
|
| Wuhan Keqian Biology Co.,Ltd
|
50
/ 100
| 17
| 65.6%
| 49.3%
| 9.7%
| €58.26K
|
| Surface Oncology, Inc.
|
50
/ 100
| -0.69
| 100.0%
| -298.0%
| -142.4%
| -€2.30M
|
| vTv Therapeutics Inc.
|
50
/ 100
| -2.2
| -47.1%
| -112,464.7%
| -73.9%
| -€729.49K
|
| BINEX Co., Ltd.
|
50
/ 100
| -30
| 26.0%
| -6.7%
| -6.3%
| -€19.63K
|
| Catalyst Biosciences, Inc.
|
50
/ 100
| -89
| 97.0%
| -19.2%
| -6.2%
| -€1.05M
|
| Fractyl Health, Inc. Common Stock
|
50
/ 100
| -0.8
| -3,235.3%
| -587,305.9%
| -160.9%
| -€800.00K
|
| Pharming Group N.V.
|
50
/ 100
| -112
| 89.3%
| 4.3%
| -1.8%
| -€17.41K
|
| Inner Mongolia Furui Medical Science Co., Ltd.
|
50
/ 100
| 70
| 73.4%
| 19.8%
| 3.8%
| €21.27K
|
| Provectus Biopharmaceuticals, Inc.
|
50
/ 100
| -5.2
| 20.2%
| -1,766.1%
| -886.4%
| -€915.63K
|
| Biome Australia Limited
|
50
/ 100
| -67
| 60.2%
| -5.2%
| -12.2%
| -€27.65K
|
| IntegraGen SA
|
50
/ 100
| -8.2
| 13.5%
| -10.4%
| -7.7%
| -€9.70K
|
| NatureWise Biotech & Medicals Corporation
|
50
/ 100
| -46
| 51.7%
| -8.9%
| -3.0%
| €0.00
|
| tella, Inc.
|
50
/ 100
| 0
| 62.7%
| 1.5%
| -2.4%
| -€10.72K
|
| Ultragenyx Pharmaceutical Inc.
|
50
/ 100
| -6.1
| 83.3%
| -86.3%
| -48.7%
| -€384.46K
|
| Aridis Pharmaceuticals, Inc.
|
50
/ 100
| -0.0039
| 100.0%
| -4.4%
| -17.5%
| -€26.48K
|
| Aditxt, Inc.
|
50
/ 100
| -0.12
| -4,949.2%
| -231,167,093.1%
| -76.9%
| -€829.45K
|
| Palatin Technologies, Inc.
|
50
/ 100
| -0.1
| 51.5%
| -6,723.2%
| -625.7%
| -€667.18K
|
| Verastem, Inc.
|
49
/ 100
| -1.4
| -247.6%
| -4,708.9%
| -136.3%
| -€2.65M
|
| Valerio Therapeutics SA
|
50
/ 100
| -0.23
| -44.2%
| -1,019.6%
| -246.9%
| -€1.17M
|
| Abpro Corporation
|
50
/ 100
| -1.2
| 100.0%
| -7,435.0%
| -365.1%
| -€1.82M
|
| Can-Fite BioPharma Ltd.
|
50
/ 100
| -1.6
| 100.0%
| -1,595.4%
| -114.0%
| -€1.51M
|
| Travere Therapeutics, Inc.
|
50
/ 100
| -15
| 56.9%
| -20.6%
| -16.4%
| -€197.32K
|
| Janux Therapeutics, Inc.
|
50
/ 100
| -15
| 89.6%
| -1,442.9%
| -9.9%
| -€960.73K
|
| GlobeImmune, Inc.
|
50
/ 100
| -0.00056
| 66.5%
| -33.3%
| -21.2%
| -€887.42K
|
| Apex Biotechnology Corp.
|
50
/ 100
| 18
| 29.3%
| 10.0%
| 6.8%
| €6.96K
|
| Daré Bioscience, Inc.
|
50
/ 100
| -1.5
| 80,447.7%
| 104,388.5%
| -143.3%
| -€760.09K
|
| Amylyx Pharmaceuticals, Inc.
|
50
/ 100
| -2.6
| 545.8%
| 79,106.4%
| -96.4%
| -€1.31M
|
| Alaunos Therapeutics, Inc.
|
50
/ 100
| -1.2
| 100.0%
| -67,266.7%
| -84.3%
| -€3.43M
|
| Mirum Pharmaceuticals, Inc.
|
50
/ 100
| -41
| 79.0%
| -13.3%
| -8.1%
| -€150.44K
|
| Yunnan Botanee Bio-Technology Group Co.LTD
|
50
/ 100
| 77
| 75.4%
| 7.3%
| 3.3%
| €8.16K
|
| Cyclacel Pharmaceuticals, Inc.
|
50
/ 100
| -1.1
| 120.0%
| 41,432.0%
| -145,603.3%
| -€458.17K
|
| Intellia Therapeutics, Inc.
|
55
/ 100
| -1.8
| 95.1%
| -968.7%
| -53.4%
| -€1.02M
|
| Athersys, Inc.
|
50
/ 100
| 0
| 101.3%
| -52,202.5%
| -504.9%
| -€1.34M
|
| Immunovant, Inc.
|
50
/ 100
| -5.9
| -16.9%
| -30,601.3%
| -79.7%
| -€1.10M
|
| PHAXIAM Therapeutics S.A.
|
50
/ 100
| -0.91
| 78.1%
| -1,023.8%
| -56.1%
| -€322.38K
|
| Nanobac Pharmaceuticals, Incorporated
|
50
/ 100
| -0.0038
| 17.6%
| 27,894.8%
| -91.1%
| -€5.64M
|
| Oneness Biotech Co., Ltd.
|
50
/ 100
| -17
| 35.7%
| -850.4%
| -16.2%
| -€291.13K
|
| Rhythm Pharmaceuticals, Inc.
|
52
/ 100
| -21
| 89.4%
| -106.8%
| -37.9%
| -€583.09K
|
| Hemagen Diagnostics, Inc.
|
50
/ 100
| -0.0017
| 39.9%
| -10.8%
| -37.1%
| -€51.90K
|
| Chengdu Olymvax Biopharmaceuticals Inc.
|
50
/ 100
| 110
| 93.8%
| 10.5%
| 3.4%
| €15.99K
|
| 89bio, Inc.
|
50
/ 100
| -3.3
| 61.9%
| -2,217,504.8%
| -74.6%
| -€4.15M
|
| First Wave BioPharma, Inc.
|
50
/ 100
| -0.13
| 69.0%
| 1,601.0%
| -24.6%
| -€2.00M
|
| PureTech Health plc
|
50
/ 100
| -15
| -321.7%
| -3,995.7%
| -5.7%
| -€299.95K
|
| Fate Therapeutics, Inc.
|
50
/ 100
| -1.1
| 54.1%
| -2,448.2%
| -45.4%
| -€739.94K
|
| Sorrento Therapeutics, Inc.
|
50
/ 100
| -0.0021
| 44.6%
| -720.9%
| -120.3%
| -€496.54K
|
| CombiGene AB (publ)
|
50
/ 100
| -1.1
| -455.5%
| -1,350.2%
| -59.1%
| -€455.39K
|
| GlycoNex Incorporation
|
50
/ 100
| -13
| 62.2%
| -581.1%
| -15.8%
| €0.00
|
| PYC Therapeutics Limited
|
50
/ 100
| -7.8
| 99.3%
| -222.6%
| -48.0%
| -€2.18M
|
| AnaptysBio, Inc.
|
51
/ 100
| -5.3
| 99.0%
| -69.9%
| -39.6%
| -€836.51K
|
| Genomictree Inc.
|
50
/ 100
| -86K
| -25.5%
| -633.4%
| -8.2%
| -€75.87K
|
| HLB Co., Ltd.
|
50
/ 100
| -49
| 20.6%
| -128.5%
| -19.2%
| -€522.73K
|
| Enanta Pharmaceuticals, Inc.
|
50
/ 100
| -1.8
| 22.5%
| -149.4%
| -30.6%
| -€602.64K
|
| Lysogene S.A.
|
50
/ 100
| -0.8
| 82.6%
| -54.5%
| -17.1%
| -€282.73K
|
| ImmunityBio, Inc.
|
50
/ 100
| -8.2
| 89.8%
| -315.8%
| 0.0%
| -€445.77K
|
| Sage Therapeutics, Inc.
|
50
/ 100
| -1.4
| 89.5%
| -461.3%
| -71.2%
| -€732.08K
|
| Lyell Immunopharma, Inc.
|
50
/ 100
| -0.42
| 100.0%
| -593,598.3%
| -86.0%
| -€947.80K
|
| TG Therapeutics, Inc.
|
51
/ 100
| 101
| 87.0%
| 18.9%
| 8.6%
| €147.37K
|
| Zentalis Pharmaceuticals, Inc.
|
50
/ 100
| -0.79
| 98.2%
| -615.2%
| -45.6%
| -€771.77K
|
| OncoZenge AB (publ)
|
50
/ 100
| -11
| 100.0%
| -251.4%
| -44.7%
| -€623.13K
|
| Innate Pharma S.A.
|
50
/ 100
| -2
| -82.6%
| -215.7%
| -86.2%
| -€442.56K
|
| CNBX Pharmaceuticals Inc.
|
50
/ 100
| -0.019
| 0.0%
| 1,107.0%
| -1,205.8%
| -€192.58K
|
| GenSight Biologics S.A.
|
50
/ 100
| -0.65
| 35.7%
| -1,055.3%
| -373.9%
| -€2.51M
|
| REGENXBIO Inc.
|
49
/ 100
| -2.9
| 50.0%
| -96.0%
| -33.9%
| -€432.44K
|
| Green Cross Holdings Corporation
|
50
/ 100
| 13
| 29.2%
| 1.2%
| 2.9%
| €458.50K
|
| Youcare Pharmaceutical Group Co., Ltd.
|
50
/ 100
| -78
| 54.1%
| -3.3%
| -1.8%
| -€3.47K
|
| Bio-Works Technologies AB (publ)
|
50
/ 100
| -3.9
| 73.4%
| -99.0%
| -66.7%
| -€102.58K
|
| Solid Biosciences Inc.
|
50
/ 100
| -2.1
| 37.6%
| -5,432.1%
| -61.0%
| -€1.43M
|
| Ampio Pharmaceuticals, Inc.
|
50
/ 100
| -0.00036
| 100.0%
| -3,884.9%
| -150.5%
| -€1.23M
|
| NexImmune, Inc.
|
50
/ 100
| -0.0000067
| 71.3%
| -1,020.0%
| -351.7%
| -€2.95M
|
| TCI GENE Inc.
|
50
/ 100
| 17
| 56.1%
| 16.5%
| 5.6%
| €0.00
|
| Spyre Therapeutics, Inc.
|
50
/ 100
| -13
| 100.0%
| 18,405.3%
| -15.4%
| -€1.03M
|
| BioLineRx Ltd.
|
50
/ 100
| -2.7
| 59.3%
| -84.1%
| -18.1%
| -€239.69K
|
| AVAX Technologies, Inc.
|
50
/ 100
| -0.00093
| 100.0%
| 1,023.2%
| -539.7%
| -€703.36K
|
| Pila Pharma AB (publ)
|
50
/ 100
| -7.5
| 18.8%
| -847.5%
| -324.0%
| -€1.03M
|
| NRx Pharmaceuticals, Inc.
|
50
/ 100
| -1.8
| 50.0%
| -325,775.0%
| -698.5%
| -€14.50M
|
| Pharmaron Beijing Co., Ltd.
|
50
/ 100
| 27
| 34.2%
| 13.5%
| 5.9%
| €8.59K
|
| Hugel, Inc.
|
50
/ 100
| 28K
| 77.0%
| 46.6%
| 14.8%
| €141.93K
|
| Hansa Biopharma AB (publ)
|
50
/ 100
| -2.9
| 67.6%
| -258.9%
| -71.2%
| -€394.55K
|
| Theranexus SA
|
50
/ 100
| -0.91
| -85.8%
| -408.4%
| -204.8%
| -€638.35K
|
| Hybrigenics SA
|
50
/ 100
| -0.41
| -1,199.7%
| -17,443.9%
| -63.1%
| -€564.22K
|
| Bellerophon Therapeutics, Inc.
|
50
/ 100
| -0.013
| 99.9%
| -195.7%
| -234.4%
| -€556.27K
|
| Zymeworks Inc.
|
50
/ 100
| -14
| 97.3%
| -52.5%
| -16.0%
| -€182.01K
|
| Arix Bioscience plc
|
50
/ 100
| -0.018
| 38.1%
| 322.6%
| -42.3%
| -€12.91M
|
| Chengzhi Shareholding Co., Ltd.
|
50
/ 100
| 81
| 14.9%
| 3.1%
| 0.4%
| €3.35K
|
| Healios K.K.
|
50
/ 100
| -8.5
| -160.7%
| -2,823.2%
| -35.5%
| -€507.98K
|
| Kringle Pharma, Inc.
|
50
/ 100
| -3.5
| 100.0%
| -1,319.9%
| -39.4%
| -€331.80K
|
| Comera Life Sciences Holdings, Inc.
|
50
/ 100
| -0.000073
| 73.5%
| -914.3%
| -2,742.6%
| -€6.02M
|
| Revolution Medicines, Inc.
|
43
/ 100
| -7.9
| 48.5%
| -396.4%
| -42.7%
| -€1.34M
|
| BioCardia, Inc.
|
50
/ 100
| -1.4
| 553.4%
| 10,103.4%
| -138.9%
| -€431.02K
|
| Chengdu Easton Biopharmaceuticals Co., Ltd.
|
50
/ 100
| 34
| 74.0%
| 18.1%
| 6.6%
| €19.80K
|
| SQZ Biotechnologies Company
|
50
/ 100
| -0.26
| 100.0%
| -600.1%
| -11.4%
| -€54.99K
|
| Finch Therapeutics Group, Inc.
|
50
/ 100
| -1.6
| 95.1%
| -693.7%
| -31.1%
| -€12.16M
|
| La Jolla Pharmaceutical Company
|
50
/ 100
| 0
| 80.9%
| -5.5%
| 1.5%
| €21.39K
|
| Ionis Pharmaceuticals, Inc.
|
49
/ 100
| -0.045
| 98.8%
| -28.8%
| -4,257.4%
| -€103.64M
|
| Pharmosa Biopharm Inc.
|
50
/ 100
| -25
| 73.1%
| -160.7%
| -14.8%
| €0.00
|
| Shanghai Haohai Biological Technology Co., Ltd.
|
50
/ 100
| 27
| 67.6%
| 14.2%
| 5.5%
| €22.31K
|
| GuiZhou SanLi Pharmaceutical Co.,Ltd
|
50
/ 100
| 20
| 69.4%
| 14.2%
| 8.2%
| €10.22K
|
| Arcus Biosciences, Inc.
|
50
/ 100
| -2.7
| 87.9%
| -156.3%
| -35.8%
| -€477.58K
|
| CymaBay Therapeutics, Inc.
|
50
/ 100
| -33
| 97.8%
| -327.2%
| -25.7%
| -€948.69K
|
| Yantai Zhenghai Biotechnology Co., Ltd.
|
50
/ 100
| 48
| 85.5%
| 23.1%
| 8.0%
| €28.15K
|
| Abcam plc
|
50
/ 100
| 0
| 69.9%
| 12.8%
| 3.5%
| €19.54K
|
| Avecho Biotechnology Limited
|
50
/ 100
| -2.2
| 30.1%
| -606.0%
| -80.2%
| -€113.36K
|
| Molecular Partners AG
|
50
/ 100
| -1.8
| 18.8%
| -9,227.9%
| -52.2%
| -€436.90K
|
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
|
50
/ 100
| 48
| 72.8%
| 61.9%
| 12.7%
| €93.38K
|
| Celyad Oncology SA
|
50
/ 100
| -1.2
| -82.2%
| -5,614.3%
| -249.8%
| -€837.12K
|
| Beijing Tiantan Biological Products Co., Ltd.
|
50
/ 100
| 30
| 46.6%
| 34.0%
| 8.0%
| €30.16K
|
| Panacea Biotec Limited
|
50
/ 100
| 246
| 61.5%
| -7.8%
| 0.0%
| €565.03
|
| Avacta Group Plc
|
50
/ 100
| -0.02
| 33.3%
| -151.6%
| -76.1%
| -€504.70K
|
| Advaxis, Inc.
|
50
/ 100
| -0.03
| -54,853.8%
| -278,969.2%
| -290.0%
| -€2.06M
|
| Xenetic Biosciences, Inc.
|
50
/ 100
| -1.5
| 75.9%
| -133.5%
| -57.6%
| -€1.32M
|
| Mabion S.A.
|
50
/ 100
| -4
| 17.7%
| -98.3%
| -27.3%
| -€44.90K
|
| Diagonal Bio AB (publ)
|
50
/ 100
| -1.7
| -419.7%
| -1,712.9%
| -34.7%
| -€232.89K
|
| Addex Therapeutics Ltd
|
50
/ 100
| -1.6
| 100.0%
| -2,624.3%
| -71.1%
| -€3.22M
|
| Fermenta Biotech Ltd.
|
50
/ 100
| 9.4
| 68.7%
| 21.5%
| 0.0%
| €17.85K
|
| Ever Supreme Bio Technology Co., Ltd
|
50
/ 100
| 36
| 69.4%
| 45.6%
| 24.5%
| €127.47K
|
| Ocuphire Pharma, Inc.
|
50
/ 100
| -0.97
| 4,247.6%
| 10,425.5%
| -157.8%
| -€2.91M
|
| Arctic Bioscience AS
|
50
/ 100
| -1.5
| 31.6%
| -95.2%
| -19.0%
| -€212.58K
|
| Jiangsu gdk Biotechnology Co., Ltd.
|
50
/ 100
| -18
| 73.0%
| -136.7%
| -6.3%
| -€24.79K
|
| Apellis Pharmaceuticals, Inc.
|
50
/ 100
| 54
| 88.8%
| 7.9%
| 4.2%
| €54.75K
|
| Atreca, Inc.
|
50
/ 100
| -0.038
| -2,420.2%
| -22,844.5%
| -360.9%
| -€906.40K
|
| Visgeneer Inc.
|
50
/ 100
| -10
| 46.2%
| -11.4%
| -9.4%
| €0.00
|
| IMBDX Inc
|
50
/ 100
| -34K
| 18.8%
| -274.3%
| -26.1%
| -€84.63K
|
| Alzinova AB (publ)
|
50
/ 100
| -7.4
| 26,037.4%
| -24,253.5%
| -16.8%
| -€439.75K
|
| Bioventix PLC
|
50
/ 100
| 0.088
| 91.7%
| 77.2%
| 126.9%
| €1.11M
|
| Concert Pharmaceuticals, Inc.
|
50
/ 100
| 0
| 100.0%
| -121,474.9%
| -38.8%
| -€890.90K
|
| Valbiotis SA
|
50
/ 100
| -0.83
| 6.5%
| -363.8%
| -88.7%
| -€395.27K
|
| Chimeric Therapeutics Limited
|
50
/ 100
| -0.42
| 89.2%
| -278.9%
| -88.9%
| €0.00
|
| TaiMed Biologics Inc.
|
50
/ 100
| -99
| 40.8%
| -42.4%
| -5.1%
| -€84.76K
|
| Genfit S.A.
|
50
/ 100
| -22
| 96.8%
| 4.1%
| -3.9%
| -€49.99K
|
| CytoTools AG
|
50
/ 100
| -0.0078
| 100.0%
| -3,217.0%
| -3,063.4%
| -€20.95M
|
| Hexima Limited
|
50
/ 100
| -1.3
| 91.2%
| -1,757.9%
| -102.0%
| €0.00
|
| Vcanbio Cell & Gene Engineering Corp., Ltd
|
50
/ 100
| 153
| 68.7%
| 6.2%
| 1.4%
| €4.11K
|
| OncoCyte Corporation
|
50
/ 100
| -1.2
| 54.5%
| -1,498.3%
| -125.5%
| -€1.18M
|
| Prestige BioPharma Limited
|
50
/ 100
| 34
| -250.6%
| -468.3%
| 3.1%
| €246.17K
|
| AnGes, Inc.
|
50
/ 100
| -0.89
| 36.6%
| -900.5%
| -494.2%
| -€2.87M
|
| Astria Therapeutics, Inc.
|
50
/ 100
| -2.6
| 100.0%
| -19,335.7%
| -45.6%
| -€1.36M
|
| Lexaria Bioscience Corp.
|
50
/ 100
| -1.8
| 99.6%
| -1,850.1%
| -169.0%
| -€1.40M
|
| ChromaDex Corporation
|
50
/ 100
| 63
| 86.9%
| 19.6%
| 19.4%
| €146.26K
|
| Beijing Kawin Technology Share-Holding Co., Ltd.
|
50
/ 100
| 33
| 82.3%
| 15.8%
| 5.6%
| €30.63K
|
| Fennec Pharmaceuticals Inc.
|
50
/ 100
| -24
| 93.1%
| -12.0%
| -14.1%
| -€186.08K
|
| Aelis Farma S.A.
|
50
/ 100
| -1.1
| 36.7%
| -133.4%
| -97.7%
| -€543.71K
|
| Nuo Therapeutics, Inc.
|
50
/ 100
| -29
| 76.0%
| -133.5%
| -181.7%
| -€235.54K
|
| Repare Therapeutics Inc.
|
50
/ 100
| -0.56
| 98.1%
| 217.9%
| -84.2%
| -€730.72K
|
| Stemcell Holdings, Inc.
|
50
/ 100
| 0.53
| 77.2%
| 48.0%
| 25.8%
| €94.96K
|
| Karyopharm Therapeutics Inc.
|
50
/ 100
| -0.3
| 95.9%
| -73.1%
| -129.5%
| -€383.24K
|
| Laboratorios Farmaceuticos Rovi, S.A.
|
50
/ 100
| 14
| 65.2%
| 26.8%
| 23.2%
| €91.68K
|
| Exscientia plc
|
50
/ 100
| -2.3
| -67.7%
| -982.2%
| -36.6%
| -€356.30K
|
| Evogene Ltd.
|
50
/ 100
| -2.1
| 46.8%
| -285.4%
| -42.0%
| -€104.51K
|
| Adaptimmune Therapeutics plc
|
50
/ 100
| -0.41
| 94.8%
| -252.3%
| -129.9%
| -€287.85K
|
| PMGC Holdings Inc.
|
50
/ 100
| -0.38
| 115.4%
| 260.5%
| -59.8%
| -€2.41M
|
| HOOKIPA Pharma Inc.
|
50
/ 100
| -0.25
| 92.5%
| -860.2%
| -119.7%
| -€767.11K
|
| Proteonomix, Inc.
|
50
/ 100
| -0.00051
| 143.5%
| -22,967.7%
| -27.1%
| €0.00
|
| Kuros Biosciences AG
|
44
/ 100
| -70
| 87.8%
| -0.5%
| -13.6%
| -€130.77K
|
| Appili Therapeutics Inc.
|
50
/ 100
| -0.79
| 92.3%
| -614.6%
| -120.5%
| -€177.86K
|
| Heron Therapeutics, Inc.
|
50
/ 100
| -23
| 73.9%
| 1.0%
| -5.5%
| -€95.49K
|
| BioSenic S.A.
|
50
/ 100
| -0.044
| 88.5%
| -304.0%
| -317.1%
| -€2.48M
|
| Xbrane Biopharma AB (publ)
|
50
/ 100
| 4.8
| 73.2%
| -18.5%
| 13.2%
| €111.62K
|
| Vir Biotechnology, Inc.
|
50
/ 100
| -1.5
| -880.9%
| -3,511.4%
| -49.0%
| -€1.05M
|
| International Stem Cell Corporation
|
50
/ 100
| -4
| 57.8%
| -0.9%
| -4.3%
| -€6.46K
|
| Steminent Biotherapeutics Inc.
|
50
/ 100
| -9.6
| -2,084.5%
| -31,217.2%
| -65.9%
| -€143.98K
|
| Chongqing Zhifei Biological Products Co., Ltd.
|
50
/ 100
| -35
| 25.8%
| -15.2%
| -2.9%
| -€22.51K
|
| 60 Degrees Pharmaceuticals, Inc.
|
50
/ 100
| -0.45
| 33.1%
| -920.6%
| -186.5%
| -€2.23M
|
| Anti-Microbial Savior BioteQ Co., Ltd
|
50
/ 100
| -18
| -1,949.4%
| -14,244.3%
| -75.5%
| €0.00
|
| Windtree Therapeutics, Inc.
|
50
/ 100
| -0.058
| 100.0%
| -30,255.6%
| -278.7%
| -€2.73M
|
| KemPharm, Inc.
|
50
/ 100
| -11
| 62.1%
| -264.0%
| -18.7%
| -€1.72M
|
| Onconova Therapeutics, Inc.
|
50
/ 100
| -0.000000062
| -51,242.6%
| -62,232.0%
| -1,065,820.1%
| -€8.93T
|
| Shattuck Labs, Inc.
|
50
/ 100
| -0.94
| 94.0%
| -373.0%
| -54.7%
| -€1.07M
|
| Armata Pharmaceuticals, Inc.
|
50
/ 100
| -2.9
| 78.1%
| -1,037.9%
| -31.8%
| -€367.61K
|
| Seagen Inc.
|
50
/ 100
| -58
| 75.4%
| -34.4%
| -20.6%
| -€197.69K
|
| Hofseth BioCare ASA
|
50
/ 100
| -5.8
| 36.0%
| -42.6%
| -34.9%
| -€159.24K
|
| Ainos, Inc.
|
50
/ 100
| -0.74
| 82.3%
| -13,151.1%
| -65.7%
| -€306.62K
|
| Sailong Pharmaceutical Group Co., Ltd.
|
50
/ 100
| -31
| 18.2%
| -28.2%
| -8.8%
| -€17.56K
|
| Celldex Therapeutics, Inc.
|
50
/ 100
| -6.7
| 85.9%
| -4,053.7%
| -28.8%
| -€920.78K
|
| Philogen S.p.A.
|
50
/ 100
| 14
| 51.6%
| 1.4%
| 28.8%
| €263.87K
|
| Vanta Bioscience Limited
|
50
/ 100
| -3.1
| -50.0%
| -216.7%
| -6.8%
| -€11.53K
|
| Orchestra BioMed Holdings, Inc.
|
50
/ 100
| -1.7
| 92.7%
| -2,420.8%
| -162.8%
| -€854.31K
|
| SMS Lifesciences India Limited
|
50
/ 100
| 21
| 30.7%
| 7.6%
| 0.0%
| €2.87K
|
| NovaBay Pharmaceuticals, Inc.
|
50
/ 100
| 1
| 64.4%
| -158.5%
| 48.1%
| €219.38K
|
| Alexion Pharmaceuticals, Inc.
|
50
/ 100
| 0
| 90.9%
| 44.0%
| 3.7%
| €152.46K
|
| Evgen Pharma plc
|
50
/ 100
| -0.0084
| 98.4%
| -1,034.6%
| -234.5%
| -€820.95K
|
| Shenzhen GuoHua Network Security Technology Co., Ltd.
|
50
/ 100
| -8.4
| 69.1%
| -179.9%
| -55.2%
| -€62.88K
|
| Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
|
50
/ 100
| 32
| 80.4%
| 21.9%
| 4.3%
| €15.14K
|
| Theralink Technologies, Inc.
|
50
/ 100
| -0.49
| 78.0%
| -1,104.2%
| -44.3%
| -€67.74K
|
| SkinBioTherapeutics Plc
|
50
/ 100
| -0.075
| 53.7%
| -196.8%
| -74.8%
| -€416.20K
|
| CHO Pharma, Inc.
|
50
/ 100
| -16
| -248.7%
| -11,644.4%
| -17.7%
| €0.00
|
| Anhui Anke Biotechnology (Group) Co., Ltd.
|
50
/ 100
| 22
| 76.0%
| 29.0%
| 13.1%
| €30.67K
|
| Kronos Bio, Inc.
|
50
/ 100
| -0.82
| 100.0%
| -765.2%
| -59.6%
| -€6.92M
|
| Sangamo Therapeutics, Inc.
|
50
/ 100
| -2
| 100.0%
| -76.9%
| -64.9%
| -€296.82K
|
| MultiCell Technologies, Inc.
|
50
/ 100
| -197
| 65.0%
| -59.6%
| -85.7%
| -€108.80
|
| Lyra Therapeutics, Inc.
|
50
/ 100
| -0.46
| 74.0%
| -5,340.1%
| -73.9%
| -€1.11M
|
| Immunome, Inc.
|
50
/ 100
| -3.7
| -408.2%
| -2,419.9%
| -74.4%
| -€1.46M
|
| X4 Pharmaceuticals, Inc.
|
50
/ 100
| -0.18
| 83.0%
| -323.1%
| -97.0%
| -€611.86K
|
| AgeX Therapeutics, Inc.
|
50
/ 100
| -23
| -43.0%
| -27,468.8%
| -30.2%
| -€578.72K
|
| Voyager Therapeutics, Inc.
|
50
/ 100
| -1.6
| 100.0%
| -447.7%
| -44.0%
| -€632.44K
|
| Cytokinetics, Incorporated
|
48
/ 100
| -6.5
| -227.0%
| -638.0%
| -49.5%
| -€1.04M
|
| Karolinska Development AB (publ)
|
50
/ 100
| -3.2
| 100.0%
| -4,525.6%
| -6.9%
| -€911.32K
|
| Guangdong VTR Bio-Tech Co., Ltd.
|
50
/ 100
| 591
| 44.8%
| 1.4%
| 0.2%
| €704.86
|
| Vivoryon Therapeutics N.V.
|
50
/ 100
| -1
| 120.6%
| 1,216.3%
| -680.3%
| -€2.91M
|
| Magle Chemoswed Holding AB (publ)
|
50
/ 100
| -27
| 65.7%
| -1.5%
| -1.9%
| -€12.52K
|
| Therapeutic Solutions International, Inc.
|
50
/ 100
| -0.00087
| 81.5%
| -1,628.3%
| -16,207.9%
| -€167.87M
|
| Immunocore Holdings plc
|
46
/ 100
| -63
| 99.3%
| -11.9%
| -2.6%
| -€49.19K
|
| SYN-TECH Chem. & Pharm. Co., Ltd.
|
50
/ 100
| 11
| 34.8%
| 24.3%
| 10.2%
| €36.30K
|
| StemCell Institute Inc.
|
50
/ 100
| 23
| 63.1%
| 15.6%
| 5.1%
| €21.66K
|
| Foghorn Therapeutics Inc.
|
50
/ 100
| -3.5
| 14.7%
| -352.9%
| -35.2%
| -€552.51K
|
| Spruce Biosciences, Inc.
|
50
/ 100
| -0.053
| 100.0%
| -3,900.4%
| -221.5%
| -€2.07M
|
| Celltrion Healthcare Co., Ltd.
|
50
/ 100
| 248
| 28.2%
| 7.8%
| 0.9%
| €169.40K
|
| C4 Therapeutics, Inc.
|
50
/ 100
| -0.91
| 94.1%
| -431.1%
| -44.9%
| -€928.83K
|
| Omeros Corporation
|
50
/ 100
| -1.7
| -48.5%
| -33,589.8%
| -61.1%
| -€520.21K
|
| Deinove SA
|
50
/ 100
| -0.095
| -4,758.2%
| -8,616.9%
| -114.7%
| -€270.81K
|
| Piramal Pharma Limited
|
50
/ 100
| 271
| 56.2%
| 15.2%
| 0.0%
| €1.39K
|
| Helixmith Co., Ltd
|
50
/ 100
| -17
| 54.7%
| -224.1%
| -5.5%
| -€35.69K
|
| Arcturus Therapeutics Holdings Inc.
|
50
/ 100
| -5.6
| 77.6%
| -61.8%
| -19.5%
| -€296.67K
|
| Precision BioSciences, Inc.
|
50
/ 100
| -0.67
| -1.6%
| -12,980.9%
| -89.4%
| -€664.17K
|
| Spago Nanomedical AB (publ)
|
50
/ 100
| -2.4
| -782.8%
| -2,085.7%
| -131.1%
| -€217.73K
|
| Bavarian Nordic A/S
|
50
/ 100
| 65
| 53.1%
| 22.2%
| 10.2%
| €115.79K
|
| ABVC BioPharma, Inc.
|
50
/ 100
| -9.3
| 79.3%
| -836.3%
| -18.8%
| -€163.89K
|
| BLIS Technologies Limited
|
50
/ 100
| 14
| 71.5%
| -0.1%
| 10.4%
| €18.90K
|
| Oyster Point Pharma, Inc.
|
50
/ 100
| 0
| 76.9%
| -839.0%
| -173.0%
| -€535.11K
|
| Idorsia Ltd
|
50
/ 100
| -3.2
| 65.7%
| -48.5%
| -26.8%
| -€223.19K
|
| ReproCELL Incorporated
|
50
/ 100
| -142
| 53.4%
| -10.8%
| -1.4%
| -€7.24K
|
| Medy-Tox Inc.
|
50
/ 100
| 58
| 57.6%
| 8.0%
| 3.3%
| €15.58K
|
| Silence Therapeutics plc
|
51
/ 100
| -0.24
| 35.0%
| -379.8%
| -10.7%
| -€97.87K
|
| Larimar Therapeutics, Inc.
|
50
/ 100
| -2
| 33.2%
| -45,036.1%
| -66.5%
| -€1.32M
|
| Rallybio Corporation
|
50
/ 100
| -0.35
| 96.1%
| -5,703.2%
| -81.7%
| -€1.43M
|
| IXICO plc
|
50
/ 100
| -0.033
| 46.2%
| -34.9%
| -24.2%
| -€48.16K
|
| ImmunoGen, Inc.
|
50
/ 100
| -119
| 98.7%
| -27.9%
| -8.9%
| -€226.34K
|
| NeuroBo Pharmaceuticals, Inc.
|
50
/ 100
| -0.77
| 50.0%
| -100,155.0%
| -100.2%
| -€1.98M
|
| argenx SE
|
50
/ 100
| 40
| 92.7%
| 2.1%
| 12.5%
| €480.19K
|
| PhaseBio Pharmaceuticals, Inc.
|
50
/ 100
| 0
| 100.0%
| 3,588.2%
| 125.6%
| €398.05K
|
| Day One Biopharmaceuticals, Inc.
|
50
/ 100
| -4.5
| 89.4%
| -123.9%
| -29.5%
| -€719.38K
|
| Aprea Therapeutics, Inc.
|
50
/ 100
| -0.73
| 96.6%
| -4,567.8%
| -80.0%
| -€1.49M
|
| Hualan Biological Engineering Inc.
|
50
/ 100
| 32
| 58.2%
| 26.9%
| 5.8%
| €28.70K
|
| Acer Therapeutics Inc.
|
50
/ 100
| 0
| 77.5%
| -7,376.2%
| -346.3%
| -€1.39M
|
| Polyphor AG
|
50
/ 100
| 0
| 100.0%
| -1,688.1%
| -50.4%
| -€1.18M
|
| Hainan Huluwa Pharmaceutical Group Co., Ltd.
|
50
/ 100
| -26
| 48.7%
| -11.9%
| -5.1%
| -€8.62K
|
| RaQualia Pharma Inc.
|
50
/ 100
| -29
| 71.3%
| -7.7%
| -5.3%
| -€45.33K
|
| Oramed Pharmaceuticals Inc.
|
50
/ 100
| -3.8
| -2.4%
| -683.7%
| -14.9%
| -€1.59M
|
| Cara Therapeutics, Inc.
|
50
/ 100
| -12
| 61.0%
| -308.2%
| -47.8%
| -€1.79M
|
| RBC Bioscience Corporation
|
50
/ 100
| 7
| 45.7%
| 15.7%
| 4.9%
| €19.49K
|
| OncoTherapy Science, Inc.
|
50
/ 100
| -7
| 2.3%
| -97.5%
| -54.1%
| -€84.52K
|
| DaShenLin Pharmaceutical Group Co., Ltd.
|
50
/ 100
| 18
| 34.2%
| 6.0%
| 4.1%
| €2.94K
|
| GeneLink, Inc.
|
50
/ 100
| -0.012
| 26.4%
| -128.6%
| -173.4%
| €0.00
|
| Anatara Lifesciences Ltd
|
50
/ 100
| -0.35
| -123.9%
| -441.2%
| -262.0%
| €0.00
|
| Beam Therapeutics Inc.
|
50
/ 100
| -4.3
| 76.1%
| -1,013.6%
| -31.6%
| -€905.25K
|
| Starpharma Holdings Limited
|
50
/ 100
| -3.6
| -0.4%
| -277.0%
| -62.4%
| -€225.88K
|
| SYBLEU Inc
|
50
/ 100
| -1.9
| 100.0%
| -2,362.6%
| -101.2%
| €0.00
|
| Curis, Inc.
|
50
/ 100
| -0.73
| 99.3%
| -332.9%
| -133.1%
| -€982.13K
|
| ReNeuron Group plc
|
50
/ 100
| -0.000036
| -299.6%
| -1,509.0%
| -197.8%
| -€558.67K
|
| ToolGen Incorporated
|
50
/ 100
| 0
| 76.5%
| -2,378.3%
| 9.4%
| €46.99K
|
| Amicus Therapeutics, Inc.
|
50
/ 100
| 95
| 90.5%
| 4.5%
| 2.3%
| €34.17K
|
| Rigel Pharmaceuticals, Inc.
|
50
/ 100
| 3.3
| 93.1%
| 42.2%
| 46.7%
| €600.07K
|
| Pieris Pharmaceuticals, Inc.
|
50
/ 100
| -0.67
| -1,260.4%
| -17,886.8%
| -36.1%
| -€496.30K
|
| Jiangsu Aidea Pharmaceutical Co., Ltd.
|
50
/ 100
| -83
| 63.3%
| -14.1%
| -3.9%
| -€19.20K
|
| eFFECTOR Therapeutics, Inc.
|
50
/ 100
| -0.000027
| 31.5%
| -20,463.6%
| -127.6%
| -€2.12M
|
| Genomic Valley Biotech Ltd.
|
50
/ 100
| 61
| 74.1%
| 42.9%
| 0.0%
| €0.00
|
| Alpine Immune Sciences, Inc.
|
50
/ 100
| -121
| 59.5%
| -90.9%
| -9.9%
| -€222.57K
|
| Awakn Life Sciences Corp.
|
50
/ 100
| -0.58
| -81.2%
| -637.2%
| -608.9%
| -€93.81K
|
| Neutra Corp.
|
50
/ 100
| -0.6
| 46.1%
| -174.3%
| -732.0%
| -€56.12K
|
| Pharmicell Co., Ltd.
|
50
/ 100
| 33
| 42.1%
| 23.3%
| 17.1%
| €89.11K
|
| Mirati Therapeutics, Inc.
|
50
/ 100
| -5.7
| -283.5%
| -2,002.7%
| -64.3%
| -€1.06M
|
| Septerna, Inc.
|
50
/ 100
| -11
| 100.0%
| -14,071.1%
| -21.1%
| -€1.00M
|
| Atrys Health, S.A.
|
50
/ 100
| -5.1
| 23.0%
| 5.1%
| -7.1%
| -€25.15K
|
| Celltrion, Inc.
|
50
/ 100
| 74
| 53.2%
| 21.2%
| 2.4%
| €120.43K
|
| Telescope Innovations Corp.
|
50
/ 100
| -29
| 100.0%
| -33.4%
| -27.1%
| €0.00
|
| BB Biotech AG
|
50
/ 100
| -3.9
| 99.3%
| 115.0%
| -23.8%
| -€46.73M
|
| Shanghai Hile Bio-Technology Co., Ltd.
|
50
/ 100
| 28
| 71.9%
| 83.1%
| 9.5%
| €57.81K
|
| Verrica Pharmaceuticals Inc.
|
52
/ 100
| -1.1
| 87.6%
| -263.4%
| -124.3%
| -€587.31K
|
| EirGenix Inc.
|
50
/ 100
| -24
| 22.4%
| -82.3%
| -8.7%
| €0.00
|
| Senhwa Biosciences, Inc.
|
50
/ 100
| -14
| 53.0%
| -29,188.3%
| -29.5%
| €0.00
|
| SAB Biotherapeutics, Inc.
|
50
/ 100
| -0.47
| -1,301.7%
| -36,462.8%
| -123.0%
| -€504.66K
|
| Nanollose Limited
|
50
/ 100
| -6.9
| -64.9%
| -927.1%
| -345.4%
| €0.00
|
| Guilin Sanjin Pharmaceutical Co., Ltd.
|
50
/ 100
| 16
| 73.6%
| 30.6%
| 12.2%
| €24.27K
|
| Guiyang Xintian Pharmaceutical Co.,Ltd.
|
50
/ 100
| 87
| 71.9%
| 4.1%
| 1.5%
| €1.72K
|
| Ascendis Pharma A/S
|
50
/ 100
| -33
| 86.8%
| -22.5%
| -20.2%
| -€229.05K
|
| Taysha Gene Therapies, Inc.
|
50
/ 100
| -7
| 95.6%
| -1,618.5%
| -31.6%
| -€1.17M
|
| Nykode Therapeutics AS
|
50
/ 100
| -27
| 100.0%
| -472.2%
| -15.3%
| -€83.23K
|
| Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.
|
50
/ 100
| 19
| 68.9%
| 28.7%
| 8.3%
| €38.29K
|
| Chimerix, Inc.
|
48
/ 100
| -9.1
| 100.0%
| -45,550.5%
| -60.5%
| -€959.95K
|
| Evofem Biosciences, Inc.
|
50
/ 100
| -0.18
| 79.7%
| -25.3%
| -43.3%
| -€167.04K
|
| Amarantus BioScience Holdings, Inc.
|
50
/ 100
| -0.076
| 100.0%
| -533.7%
| 0.0%
| €0.00
|
| Titan Biotech Limited
|
50
/ 100
| 16
| 53.2%
| 13.5%
| 0.0%
| €4.67K
|
| Vectorite Biomedical Inc.
|
50
/ 100
| -15
| 33.3%
| -35.5%
| -10.4%
| €0.00
|
| MetaStat, Inc.
|
50
/ 100
| -0.00037
| 100.0%
| 1,375.7%
| -436.0%
| -€454.88K
|
| Coherus BioSciences, Inc.
|
50
/ 100
| 0.52
| 56.1%
| -97.7%
| 40.9%
| €676.43K
|
| scPharmaceuticals Inc.
|
50
/ 100
| -2.4
| 68.5%
| -133.2%
| -114.3%
| -€485.76K
|
| Ginkgo Bioworks Holdings, Inc.
|
50
/ 100
| -1.8
| 82.2%
| -135.7%
| -25.6%
| -€324.26K
|
| Novogene Co., Ltd.
|
50
/ 100
| 29
| 43.3%
| 10.7%
| 5.4%
| €10.89K
|
| Public Joint-Stock Company "Pharmsynthez"
|
50
/ 100
| -4.6
| 25.1%
| -50.7%
| -13.9%
| -€27.92K
|
| BiOptic Inc.
|
50
/ 100
| 32
| 63.8%
| 14.5%
| 8.3%
| €0.00
|
| ORIENT BIO Inc.
|
50
/ 100
| -13
| 18.7%
| -15.6%
| -10.3%
| -€39.97K
|
| ALTEOGEN Inc.
|
50
/ 100
| 232
| 74.9%
| 47.7%
| 15.6%
| €380.53K
|
| Lexicon Pharmaceuticals, Inc.
|
50
/ 100
| -2.1
| 98.9%
| -202.6%
| -53.5%
| -€1.00M
|
| Cyxone AB (publ)
|
50
/ 100
| -0.31
| 111.4%
| -984.2%
| -65.4%
| -€657.17K
|
| Quantum-Si incorporated
|
50
/ 100
| -2.8
| 51.7%
| -3,956.0%
| -44.9%
| -€672.86K
|
| Sagittarius Life Science Corp
|
50
/ 100
| -68
| 17.8%
| -13.0%
| -4.7%
| €0.00
|
| Onconetix, Inc.
|
50
/ 100
| -0.037
| 66.4%
| -3,489.0%
| -231.1%
| -€3.16M
|
| NGM Biopharmaceuticals, Inc.
|
50
/ 100
| -0.92
| 26.3%
| -3,429.1%
| -82.8%
| -€869.37K
|
| Carisma Therapeutics, Inc.
|
50
/ 100
| -0.51
| 90.5%
| -428.3%
| -985.2%
| -€920.99K
|
| Trevena, Inc.
|
50
/ 100
| -0.026
| -264.9%
| -5,869.3%
| -177.3%
| -€1.27M
|
| Zenas BioPharma, Inc.
|
50
/ 100
| -2.9
| 99.9%
| -1,327.3%
| -60.4%
| -€1.17M
|
| Syngen Biotech Co.,Ltd.
|
50
/ 100
| 13
| 36.3%
| 16.3%
| 8.9%
| €0.00
|
| Immuno-Biological Laboratories Co., Ltd.
|
50
/ 100
| 18
| 65.4%
| 21.6%
| 13.5%
| €24.07K
|
| AdAlta Limited
|
50
/ 100
| -0.2
| 85.8%
| -446.8%
| -461.5%
| -€625.77K
|
| Verona Pharma plc
|
58
/ 100
| -95
| 95.2%
| -25.3%
| -14.2%
| -€333.29K
|
| Amarin Corporation plc
|
50
/ 100
| -64
| 44.2%
| -45.5%
| -13.1%
| -€268.92K
|
| Genkyotex SA
|
50
/ 100
| 0
| 100.0%
| -2,180.4%
| -59.7%
| -€1.11M
|
| Hunan Jiudian Pharmaceutical Co., Ltd.
|
50
/ 100
| 18
| 73.8%
| 17.0%
| 12.8%
| €25.63K
|
| Oncolys BioPharma Inc.
|
50
/ 100
| -6.9
| 99.8%
| -7,549.8%
| -116.1%
| -€309.33K
|
| JiangSu WuZhong Pharmaceutical Development Co., Ltd.
|
50
/ 100
| -29
| 96.5%
| -7.3%
| -1.7%
| -€6.87K
|
| Xintela AB (publ)
|
50
/ 100
| -7
| 94.9%
| -1,419.3%
| -465.8%
| -€183.87K
|
| Dicerna Pharmaceuticals, Inc.
|
50
/ 100
| 0
| 100.0%
| -62.9%
| -16.1%
| -€353.54K
|
| Xcell Therapeutics, Inc.
|
50
/ 100
| -2.8
| -89.0%
| -564.2%
| -69.3%
| -€95.85K
|
| Mabwell (Shanghai) Bioscience Co., Ltd.
|
50
/ 100
| -10
| 75.9%
| -622.4%
| -25.7%
| -€98.61K
|
| ABIONYX Pharma SA
|
50
/ 100
| -5.5
| 18.8%
| -91.8%
| -61.4%
| -€156.27K
|
| ADMA Biologics, Inc.
|
50
/ 100
| 25
| 54.7%
| 34.2%
| 36.8%
| €262.34K
|
| Nicox S.A.
|
50
/ 100
| -0.87
| 24.6%
| 124.0%
| -25.7%
| -€567.03K
|
| Viropro Inc.
|
50
/ 100
| -0.057
| 100.0%
| -198.1%
| -5.8%
| €0.00
|
| Clene Inc.
|
50
/ 100
| -1.2
| 82.2%
| -11,328.5%
| -136.7%
| -€348.87K
|
| Centessa Pharmaceuticals plc
|
45
/ 100
| -6.9
| 97.4%
| -1,425.3%
| -54.1%
| -€2.70M
|
| GeneReach Biotechnology Corp.
|
50
/ 100
| -7.1
| 65.0%
| -47.3%
| -14.6%
| €0.00
|
| Nanoform Finland Oyj
|
50
/ 100
| -2.9
| 85.1%
| -751.3%
| -36.2%
| -€124.54K
|
| Homology Medicines, Inc.
|
50
/ 100
| -0.57
| -0.4%
| 3,600.6%
| -54.7%
| -€4.43M
|
| Pulike Biological Engineering, Inc.
|
50
/ 100
| 37
| 59.5%
| 13.1%
| 4.4%
| €9.76K
|
| Genprex, Inc.
|
50
/ 100
| -0.5
| 0.0%
| -134,539.7%
| -451.6%
| -€988.76K
|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong
|
50
/ 100
| 10
| 19.5%
| 9.7%
| 7.4%
| €16.73K
|
| Inventiva S.A.
|
50
/ 100
| -0.98
| 92.2%
| -565.7%
| -232.6%
| -€3.64M
|
| Maze Therapeutics, Inc.
|
50
/ 100
| -14
| 74.0%
| -5,033.2%
| -29.0%
| -€604.10K
|
| Graphite Bio, Inc.
|
50
/ 100
| -31
| 177.5%
| 947.8%
| -12.6%
| -€3.93M
|
| Alnylam Pharmaceuticals, Inc.
|
71
/ 100
| 895
| 84.0%
| 8.2%
| 0.9%
| €16.76K
|
| HCW Biologics Inc.
|
50
/ 100
| -0.59
| 20.0%
| -1,474.5%
| -74.6%
| -€513.70K
|
| MediciNova, Inc.
|
50
/ 100
| -5.7
| 13.6%
| -9,883.0%
| -23.7%
| -€779.60K
|
| Cue Biopharma, Inc.
|
50
/ 100
| -1.2
| 98.8%
| -475.2%
| -95.5%
| -€813.95K
|
| NanoGroup S.A.
|
50
/ 100
| -12
| -203.9%
| -4,346.9%
| -42.1%
| -€35.97K
|
| Cartesian Therapeutics, Inc.
|
50
/ 100
| -7.5
| 100.0%
| -8,577.6%
| -9.3%
| -€471.38K
|
| Jiangsu Sihuan Bioengineering Co., Ltd
|
50
/ 100
| -25
| 42.9%
| -28.3%
| -20.8%
| -€46.94K
|
| Santhera Pharmaceuticals Holding AG
|
50
/ 100
| -62
| 69.3%
| 1.3%
| -2.1%
| -€36.71K
|
| Monte Rosa Therapeutics, Inc.
|
50
/ 100
| 13
| 97.6%
| 8.4%
| 6.7%
| €146.03K
|
| Marker Therapeutics, Inc.
|
50
/ 100
| -1.5
| -54.9%
| -280.8%
| -98.9%
| -€2.51M
|
| Intercept Pharmaceuticals, Inc.
|
50
/ 100
| -14
| 99.8%
| -19.6%
| -14.9%
| -€147.47K
|
| Pell Bio-Med Technology Co., Ltd.
|
50
/ 100
| -70
| -19.5%
| -1,388.8%
| -21.4%
| -€104.19K
|
| Zhejiang Ausun Pharmaceutical Co., Ltd.
|
50
/ 100
| 40
| 53.8%
| 31.9%
| 6.3%
| €20.30K
|
| Asep Medical Holdings Inc
|
50
/ 100
| -1.2
| -95.3%
| -2,048.5%
| -19.1%
| -€480.14K
|
| Savara Inc.
|
50
/ 100
| -3.5
| 22.8%
| -43,164.0%
| -67.4%
| -€1.60M
|
| Japan Tissue Engineering Co., Ltd.
|
50
/ 100
| -87
| 60.7%
| -9.6%
| -4.6%
| -€7.50K
|
| Biovica International AB (publ)
|
50
/ 100
| -0.8
| 93.8%
| -995.9%
| -134.9%
| -€307.79K
|
| Codexis, Inc.
|
50
/ 100
| -3
| 77.6%
| -100.1%
| -47.0%
| -€296.54K
|
| Prime Medicine, Inc.
|
50
/ 100
| -1
| 27.8%
| -4,116.6%
| -71.4%
| -€798.96K
|
| Lifecome Biochemistry Co.,Ltd.
|
50
/ 100
| -9.9
| -3.4%
| -53.3%
| -26.8%
| -€45.33K
|
| Chiasma, Inc.
|
50
/ 100
| 0
| 95.8%
| -2,408.6%
| -56.4%
| -€918.68K
|
| OSR Holdings, Inc.
|
50
/ 100
| -0.65
| -40.4%
| 2,156.8%
| -7.2%
| -€601.26K
|
| Kubota Pharmaceutical Holdings Co., Ltd.
|
50
/ 100
| -3.4
| -1,727.3%
| -3,231.4%
| -91.8%
| -€323.33K
|
| BioNTech SE
|
66
/ 100
| -64
| 79.7%
| -30.6%
| -1.6%
| -€51.31K
|
| Noxopharm Limited
|
50
/ 100
| -2.2
| -10.2%
| -324.6%
| -184.7%
| €0.00
|
| Affymax, Inc.
|
50
/ 100
| 0.011
| 99.5%
| -12,978.4%
| 50.0%
| €1.16M
|
| PeptiDream Inc.
|
50
/ 100
| -45
| 40.4%
| -32.3%
| -6.4%
| -€44.70K
|
| Creative Medical Technology Holdings, Inc.
|
50
/ 100
| -1
| -452.4%
| -98,147.2%
| -81.1%
| -€1.24M
|
| Hcmed
|
50
/ 100
| -13
| 40.7%
| -110.7%
| -47.3%
| -€78.95K
|
| Provention Bio, Inc.
|
50
/ 100
| -21
| 96.0%
| -993.9%
| -47.7%
| -€557.08K
|
| AnteoTech Limited
|
50
/ 100
| -1.8
| 102.6%
| 1,662.6%
| -207.2%
| -€317.16K
|
| Oncodesign SA
|
50
/ 100
| 0
| 41.6%
| -2.1%
| -3.8%
| -€7.23K
|
| VYNE Therapeutics Inc.
|
50
/ 100
| -0.4
| 100.0%
| -8,949.6%
| -86.2%
| -€2.54M
|
| SpringWorks Therapeutics, Inc.
|
50
/ 100
| -14
| 93.2%
| -120.5%
| -50.2%
| -€592.05K
|
| EASY BIO,Inc.
|
50
/ 100
| 8.7
| 23.6%
| 8.3%
| 6.6%
| €80.36K
|
| Egetis Therapeutics AB (publ)
|
50
/ 100
| -4.9
| 39.9%
| -693.9%
| -51.5%
| -€810.42K
|
| Jubilant Ingrevia Limited
|
50
/ 100
| 39
| 49.4%
| 9.5%
| 0.0%
| €11.58K
|
| Simcere Pharmaceutical Group Limited
|
50
/ 100
| 24
| 80.7%
| 14.9%
| 8.8%
| €20.44K
|
| Acrux Limited
|
50
/ 100
| -0.76
| -63.9%
| -299.8%
| -162.6%
| -€155.64K
|
| Linical Co., Ltd.
|
50
/ 100
| -11
| 21.5%
| -6.1%
| -4.2%
| -€5.28K
|
| VistaGen Therapeutics, Inc.
|
50
/ 100
| -1.2
| 48.9%
| -9,233.1%
| -80.9%
| -€997.07K
|
| Ernexa Therapeutics Inc.
|
50
/ 100
| -0.23
| 101.0%
| -2,087.5%
| -576.4%
| -€6.25M
|
| ObsEva SA
|
50
/ 100
| 1.7
| 54.1%
| 3.4%
| 87.8%
| €453.14K
|
| Avalo Therapeutics, Inc.
|
50
/ 100
| -1.1
| 211.8%
| -13,641.0%
| -36.5%
| -€1.72M
|
| Nektar Therapeutics
|
50
/ 100
| -0.97
| 83.2%
| -134.5%
| -58.9%
| -€1.72M
|
| IDEAYA Biosciences, Inc.
|
50
/ 100
| -12
| 3.0%
| -97.2%
| -13.5%
| -€1.05M
|
| Lipigon Pharmaceuticals AB (publ)
|
50
/ 100
| -1.5
| -886.8%
| -2,662.4%
| -132.8%
| -€537.07K
|
| United Therapeutics Corporation
|
61
/ 100
| 9.8
| 88.6%
| 47.7%
| 17.3%
| €836.11K
|
| Longeveron Inc.
|
50
/ 100
| -1.1
| 78.8%
| -941.1%
| -110.7%
| -€636.26K
|
| aTyr Pharma, Inc.
|
50
/ 100
| -6.4
| 58.5%
| 1,681.1%
| -74.4%
| -€1.16M
|
| Rapid Dose Therapeutics Corp.
|
50
/ 100
| -5.8
| 53.3%
| -148.7%
| -122.0%
| €0.00
|
| Spectrum Pharmaceuticals, Inc.
|
50
/ 100
| -3.2
| 88.7%
| -246.4%
| -60.4%
| -€649.05K
|
| Pharmala Biotech Holdings Inc.
|
50
/ 100
| -5.2
| -97.6%
| -509.5%
| -56.1%
| €0.00
|
| Invex Therapeutics Ltd
|
50
/ 100
| -3.2
| 100.0%
| -281.4%
| -38.8%
| €0.00
|
| Ovid Therapeutics Inc.
|
50
/ 100
| -0.59
| 98.5%
| -625.0%
| -49.3%
| -€1.42M
|
| Fortress Biotech, Inc.
|
50
/ 100
| -4.2
| 70.9%
| -176.6%
| -9.2%
| -€125.13K
|
| Stella Pharma Corporation
|
50
/ 100
| -75
| 85.9%
| -9.5%
| -2.6%
| -€17.67K
|
| IntelGenx Technologies Corp.
|
50
/ 100
| -2.7
| -83.1%
| -998.7%
| -168.4%
| -€197.16K
|
| Lumosa Therapeutics Co., Ltd.
|
50
/ 100
| -78
| 49.2%
| -1,129.5%
| -35.9%
| -€401.98K
|
| Microbix Biosystems Inc.
|
50
/ 100
| -130
| 55.8%
| -0.9%
| -0.8%
| -€2.02K
|
| BioXcel Therapeutics, Inc.
|
50
/ 100
| -0.21
| -151.6%
| -6,314.2%
| -197.6%
| -€1.18M
|
| Sinocelltech Group Limited
|
50
/ 100
| -461
| 95.0%
| 7.3%
| -1.3%
| -€2.49K
|
| Nutriband Inc.
|
50
/ 100
| -8.3
| 33.2%
| -264.0%
| -100.9%
| -€2.94M
|
| Chiome Bioscience Inc.
|
50
/ 100
| -9.3
| 57.8%
| -123.2%
| -44.6%
| -€115.35K
|
| Roquefort Therapeutics plc
|
52
/ 100
| -0.0085
| 86.2%
| -551.0%
| -47.2%
| -€443.69K
|
| Corcept Therapeutics Incorporated
|
60
/ 100
| 72
| 98.2%
| 8.8%
| 12.8%
| €180.50K
|
| Scorpius Holdings, Inc.
|
50
/ 100
| -0.000000039
| 35.3%
| -634.8%
| -265.5%
| -€597.00B
|
| Sarepta Therapeutics, Inc.
|
54
/ 100
| -14
| 21.4%
| -5.2%
| -7.8%
| -€169.80K
|
| Saniona AB (publ)
|
50
/ 100
| 5.7
| 98.5%
| 67.5%
| 50.8%
| €890.02K
|
| PTC Therapeutics, Inc.
|
46
/ 100
| 5.4
| 90.8%
| 43.6%
| 28.4%
| €686.88K
|
| Zota Health Care Limited
|
50
/ 100
| -50
| 53.1%
| -16.7%
| -12.8%
| -€12.08K
|
| Basilea Pharmaceutica AG
|
50
/ 100
| 9.9
| 60.9%
| 16.7%
| 25.8%
| €416.37K
|
| Humacyte, Inc.
|
50
/ 100
| -6.7
| 46.0%
| -1,382.5%
| -42.3%
| -€230.88K
|
| Exelixis, Inc.
|
50
/ 100
| 17
| 96.6%
| 35.0%
| 24.0%
| €507.10K
|
| Supriya Lifescience Limited
|
50
/ 100
| 32
| 63.9%
| 33.4%
| 0.0%
| €37.88K
|
| Memphasys Limited
|
50
/ 100
| -1.1
| -203.5%
| -1,329.7%
| -85.1%
| -€222.80K
|
| HLB Therapeutics Co.,Ltd.
|
50
/ 100
| -220K
| 17.7%
| -6.6%
| -2.4%
| -€31.93K
|
| TScan Therapeutics, Inc.
|
50
/ 100
| -0.7
| 89.8%
| -2,072.1%
| -45.8%
| -€586.77K
|
| Agios Pharmaceuticals, Inc.
|
49
/ 100
| -5
| 84.4%
| -1,061.8%
| -29.0%
| -€708.41K
|
| Plus Therapeutics, Inc.
|
50
/ 100
| -0.53
| 89.1%
| -366.4%
| -110.2%
| -€840.68K
|
| Feng Chi Biotech Corp.
|
50
/ 100
| 9
| 44.9%
| 10.0%
| 11.4%
| €30.01K
|
| Renascience Inc.
|
50
/ 100
| 212
| 96.9%
| -134.8%
| 6.1%
| €156.28K
|
| Cellectis S.A.
|
50
/ 100
| -2.1
| 92.1%
| -80.3%
| -16.7%
| -€234.35K
|
| Enzolytics Inc.
|
50
/ 100
| -0.65
| 77.8%
| -2,935.3%
| -1.8%
| -€3.14M
|
| Sunmax Biotechnology Co., Ltd.
|
50
/ 100
| 31
| 74.6%
| 52.9%
| 29.2%
| €0.00
|
| TaiRx, Inc.
|
50
/ 100
| -8.6
| -0.1%
| -1,626.9%
| -53.5%
| €0.00
|
| JETEMA, Co., Ltd.
|
50
/ 100
| -55
| 45.2%
| 2.6%
| -1.9%
| -€11.75K
|
| Encell Co. Ltd.
|
50
/ 100
| -7.6
| -67.4%
| -324.1%
| -38.8%
| -€95.31K
|
| Lisata Therapeutics, Inc.
|
50
/ 100
| -1.1
| 88.0%
| -1,962.6%
| -75.2%
| -€624.46K
|
| Bio Preventive Medicine Corp.
|
50
/ 100
| -7
| -18.0%
| -1,247.4%
| -36.9%
| -€184.77K
|
| Sprint Bioscience AB (publ)
|
50
/ 100
| -1.8
| 38.0%
| -50.8%
| -119.6%
| -€61.64K
|
| Abpro Holdings Inc
|
50
/ 100
| -0.76
| -61.2%
| -7,435.0%
| -365.1%
| -€1.82M
|
| LabTurbo Biotech Corporation
|
50
/ 100
| -11
| -39.9%
| -283.2%
| -8.2%
| €0.00
|
| Precigen, Inc.
|
47
/ 100
| -1.8
| 25.3%
| -1,798.2%
| -144.1%
| -€1.48M
|
| Biocon Limited
|
50
/ 100
| 110
| 65.4%
| 18.7%
| 0.6%
| €2.25K
|
| BeiGene, Ltd.
|
50
/ 100
| -147
| 85.5%
| -2.2%
| -2.8%
| -€13.86K
|
| E-therapeutics Plc
|
50
/ 100
| -0.029
| 65.8%
| -3,030.6%
| -77.9%
| -€653.74K
|
| MedPacto, Inc.
|
50
/ 100
| -11
| 9.3%
| -1,051.5%
| -21.3%
| -€123.36K
|
| Syngene International Limited
|
50
/ 100
| 53
| 65.4%
| 25.0%
| 7.6%
| €7.42K
|
| Humanigen, Inc.
|
50
/ 100
| 0
| 100.0%
| -3,061.2%
| -1,041.9%
| -€7.62M
|
| Immuron Limited
|
50
/ 100
| -1.3
| 66.5%
| -105.7%
| -120.0%
| -€989.31K
|
| Fermentalg SA
|
50
/ 100
| -2
| -29.4%
| -210.3%
| -47.8%
| -€421.44K
|
| HeXun Biosciences Co., Ltd.
|
50
/ 100
| 16
| 88.5%
| 51.0%
| 21.2%
| €101.62K
|
| 2cureX AB (publ)
|
50
/ 100
| -3
| -1,012.4%
| -2,356.4%
| -349.7%
| -€160.78K
|
| Opiant Pharmaceuticals, Inc.
|
50
/ 100
| -3.2
| 98.0%
| -16.5%
| -79.8%
| -€776.60K
|
| Abeona Therapeutics Inc.
|
50
/ 100
| 3.9
| -241.0%
| -20,802.3%
| 35.6%
| €519.53K
|
| Dimerix Limited
|
50
/ 100
| -11
| 100.0%
| -924.9%
| -33.3%
| €0.00
|
